Please sign in to follow a disease.
Liver disorder
MONDO:0005154A disease involving the liver.
Also known as: disease of liver, disease or disorder of liver, disorder of liver, hepatic disease, hepatic disorder, liver and intrahepatic bile duct disorder, liver disease, liver disease or disorder
3097 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsSub-types
Broader categories
Showing the 400 most recently updated of 717 trials in this tab.
-
On-the-Spot hep c care at methadone clinics boosts cure rates
⭐️ CURE ⭐️ CompletedThis study tested whether offering hepatitis C (HCV) treatment right at methadone clinics helps more people get cured compared to sending them to outside specialists. Over 600 adults on opioid addiction therapy took part across 13 clinics in Ukraine. Some clinics provided simplif…
Phase: NA • Sponsor: Ukrainian Institute on Public Health Policy • Aim: ⭐️ CURE ⭐️
Last updated Jun 27, 2026 12:29 UTC
-
New hope for tough hepatitis c: 4-Drug cocktail aims for cure in Non-Responders
⭐️ CURE ⭐️ CompletedThis study tested a combination of four drugs (asunaprevir, daclatasvir, ribavirin, and pegylated interferon) in 60 adults with hepatitis C genotype 4 who had not responded to standard treatment. The goal was to see if this stronger therapy could clear the virus completely, with …
Phase: PHASE2 • Sponsor: ANRS, Emerging Infectious Diseases • Aim: ⭐️ CURE ⭐️
Last updated Jun 27, 2026 12:06 UTC
-
Could a Lower-Dose polio vaccine help eradicate the disease?
⭐️ VACCINE ⭐️ CompletedThis study tests a hexavalent vaccine that protects against six diseases, including polio, but uses a lower dose of the inactivated polio vaccine (IPV). The goal is to see if this reduced-dose version works as well as the standard full-dose vaccine in infants. Around 1,500 health…
Phase: PHASE3 • Sponsor: Serum Institute of India Pvt. Ltd. • Aim: ⭐️ VACCINE ⭐️
Last updated Jul 03, 2026 00:00 UTC
-
New vaccine aims to train body to fight hepatitis b
⭐️ VACCINE ⭐️ CompletedThis early-stage trial tested a new two-part vaccine designed to treat chronic hepatitis B. It involved 26 healthy adults to check safety and immune response. The vaccine uses a protein first shot followed by a booster to teach the immune system to attack the virus.
Phase: PHASE1 • Sponsor: Universitätsklinikum Hamburg-Eppendorf • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 13:02 UTC
-
Double-Dose vaccine may protect HIV patients from hepatitis b
⭐️ VACCINE ⭐️ CompletedThis study tested whether a double-dose hepatitis B vaccine (40 micrograms) works better than the standard dose (20 micrograms) in people with HIV who did not respond to earlier hepatitis B shots. The goal was to see if the stronger dose could help their immune system produce eno…
Phase: PHASE3 • Sponsor: ANRS, Emerging Infectious Diseases • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 12:04 UTC
-
HIV patients get new hope against hepatitis b with tailored vaccine strategy
⭐️ VACCINE ⭐️ CompletedThis study tested three different ways of giving the hepatitis B vaccine to 437 people with HIV whose CD4 counts were above 200. The goal was to see which schedule—standard dose, double dose, or skin injections—works best to protect them from hepatitis B, a virus that can cause s…
Phase: PHASE3 • Sponsor: ANRS, Emerging Infectious Diseases • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 12:04 UTC
-
Hexaxim vaccine safety confirmed in 713 infants
⭐️ VACCINE ⭐️ CompletedThis completed study checked the safety of the Hexaxim vaccine in 713 infants aged 2 months and older in South Korea. Researchers tracked side effects like injection site reactions, fever, and crying after routine vaccination. The goal was to confirm the vaccine's safety in every…
Sponsor: Sanofi Pasteur, a Sanofi Company • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 09:06 UTC
-
Double-Barreled chemo attack on bile duct cancer shows promise
Disease control CompletedThis study tests a two-pronged chemotherapy approach for people with intrahepatic cholangiocarcinoma (a type of bile duct cancer) that cannot be removed by surgery. Participants receive chemotherapy directly to the liver through a surgically placed pump, plus standard chemotherap…
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Telehealth program aims to get HIV treatment to people who inject drugs faster
Disease control CompletedThis study tested two ways to offer HIV treatment, hepatitis C treatment, and substance use disorder medications to people who inject drugs. One group received a telehealth-enhanced program with on-demand services like mobile blood draws and counseling, while the other group got …
Phase: NA • Sponsor: University of Miami • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
Immunotherapy drug durvalumab may be safe for liver cancer patients with active hepatitis b
Disease control CompletedThis study tests whether the immunotherapy drug durvalumab can be safely given to people with advanced liver cancer who also have an active hepatitis B infection. All participants receive an antiviral drug (entecavir) to control the hepatitis B virus. The main goal is to see if d…
Phase: PHASE2 • Sponsor: National Taiwan University Hospital • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New combo therapy aims to stop liver cancer from coming back
Disease control CompletedThis study tests whether adding a targeted drug (Donafenib) and chemotherapy directly into the liver's blood supply can prevent liver cancer from returning after surgery. It includes adults with a single large tumor (≥5 cm) and microscopic blood vessel invasion, who are at high r…
Phase: PHASE2 • Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
Could a probiotic supplement help reverse fatty liver?
Disease control CompletedThis study tests whether a daily probiotic lysate supplement can reduce fat and stiffness in the liver of adults with non-alcoholic fatty liver disease (NAFLD). Participants take either the supplement or a placebo for three months, and doctors measure changes using MRI and ultras…
Phase: NA • Sponsor: Bogomolets National Medical University • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New hope for kids with liver cancer: personalized treatment shows promise
Disease control CompletedThis study tests a treatment plan tailored to each child's risk level for a rare liver cancer called hepatoblastoma. About 236 children will receive standard treatments like surgery and chemotherapy, plus the drug temsirolimus for high-risk cases. The goal is to see if this appro…
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
Could a probiotic supplement help reverse fatty liver?
Disease control CompletedThis study tests whether a daily capsule containing fragments of a probiotic bacterium (L. rhamnosus) can reduce liver fat and improve blood markers in adults with metabolic dysfunction-associated steatotic liver disease (MASLD). Participants take either the supplement or a place…
Phase: NA • Sponsor: Bogomolets National Medical University • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
Immunotherapy-Targeted therapy combo shows promise for advanced liver cancer
Disease control CompletedThis clinical trial is testing a combination of two drugs—an immunotherapy (pembrolizumab/quavonlimab) and a targeted therapy (lenvatinib)—as a first treatment for people with advanced hepatocellular carcinoma, a type of liver cancer that cannot be removed by surgery. The study a…
Phase: PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New drug naderin may help patients fight infections during cancer and TB therapy
Disease control CompletedThis study tested whether adding Naderin (sodium nucleinate) to standard treatment could reduce complications in 75 patients with cancer, tuberculosis, or hepatitis C. The main group received Naderin plus standard therapy, while the control group received standard therapy alone. …
Phase: PHASE2, PHASE3 • Sponsor: MIPO Clinic • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
Heartburn drug could ease painful sun sensitivity
Disease control CompletedThis Phase 2 trial tested whether oral cimetidine (Tagamet), a common heartburn drug, can reduce light sensitivity in people with erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP). These genetic conditions cause severe pain from sunlight exposure. The study en…
Phase: PHASE2 • Sponsor: Amy K. Dickey, M.D. • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Immunotherapy duo before liver surgery shows promise against cancer
Disease control CompletedThis trial investigates whether giving two immunotherapy drugs, ipilimumab and nivolumab, before liver surgery can help shrink tumors in people with liver cancer (hepatocellular carcinoma). Participants receive the drugs in the weeks leading up to their planned surgery. The study…
Phase: PHASE1, PHASE2 • Sponsor: Imperial College London • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Can Omega-3 and diet advice tame fatty liver disease?
Disease control CompletedThis study investigates whether a nutrition education program and omega-3 supplements can help people with non-alcoholic fatty liver disease (NAFLD) lose weight, improve liver enzymes, and lower cholesterol. Participants are randomly assigned to receive nutrition guidance, omega-…
Phase: NA • Sponsor: Hawler Medical University • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New drug combo shows promise in liver cancer trial
Disease control CompletedThis phase 2 trial tested whether adding an experimental drug called SRF388 to a standard two-drug regimen (atezolizumab plus bevacizumab) helps people with advanced liver cancer that hasn't been treated before. The study enrolled 30 adults whose cancer could not be surgically re…
Phase: PHASE2 • Sponsor: Coherus Oncology, Inc. • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New hepatitis b drug shows promise in first human tests
Disease control CompletedThis early-phase trial tested an experimental drug called BW-20507 in 32 people. First, healthy volunteers received a single dose to check safety. Then, people with chronic hepatitis B received multiple doses to see how the drug behaves in the body and whether it fights the virus…
Phase: PHASE1 • Sponsor: Shanghai Argo Biopharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New combo pill aims to halt liver scarring in NASH patients
Disease control CompletedThis completed Phase 2 study tested whether a combination of two experimental drugs, K-877-ER and CSG452, can improve liver health in adults with nonalcoholic steatohepatitis (NASH) and liver fibrosis. The 228 participants received either the combination or a placebo. The main go…
Phase: PHASE2 • Sponsor: Kowa Research Institute, Inc. • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New drug cocktail aims to make inoperable abdominal cancers operable
Disease control CompletedThis phase 2 trial tested a combination of two drugs—paclitaxel (given intravenously and directly into the abdomen) and oral nilotinib—in 21 adults with cancers that had spread to the lining of the abdomen and could not be surgically removed. The goal was to see if the treatment …
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
New pill shows promise against fatty liver disease in Mid-Stage trial
Disease control CompletedThis study tested an experimental drug called HSK31679 in 186 Chinese adults with non-alcoholic steatohepatitis (NASH), a serious liver condition. Participants took either 80 mg, 160 mg, or a placebo daily for 52 weeks. The goal was to see if the drug could improve liver damage a…
Phase: PHASE2 • Sponsor: Haisco Pharmaceutical Group Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Hope for rare liver disease: drug aims to ease severe itching in children
Disease control CompletedThis study tests the long-term safety of maralixibat, an oral medication, in children with progressive familial intrahepatic cholestasis (PFIC), a rare liver disease that causes intense itching. Participants who completed a prior study will receive maralixibat twice daily. Resear…
Phase: PHASE3 • Sponsor: Mirum Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Liver cancer drug combo shows promise in large trial
Disease control CompletedThis study tested whether adding the chemotherapy drug doxorubicin to the targeted therapy sorafenib helps people with advanced liver cancer live longer. Over 350 patients received either sorafenib alone or sorafenib plus doxorubicin. The main goal was to compare overall survival…
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Fish oil supplement tested for muscle loss in liver cancer patients
Disease control CompletedThis completed trial tested whether a daily EPA (an omega-3 fatty acid) supplement could help preserve muscle mass and reduce inflammation in 18 people with advanced liver cancer that could not be surgically removed. Participants took either the EPA supplement or a placebo for 12…
Phase: NA • Sponsor: Instituto de Investigación Sanitaria Aragón • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Hormone drug may slow Aging-Related diseases in rare condition
Disease control CompletedThis study tested whether low doses of the hormone drug danazol can slow the shortening of telomeres—the protective caps on DNA—in people with telomere diseases. These conditions can cause bone marrow failure, lung scarring, and liver damage. Eighteen participants took danazol fo…
Phase: PHASE2 • Sponsor: National Heart, Lung, and Blood Institute (NHLBI) • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New drug targets fatty liver in genetically At-Risk patients
Disease control CompletedThis early-stage trial tested a new drug, LY3849891, in 115 people with fatty liver disease who carry a specific gene variant (PNPLA3 I148M). The main goal was to check safety and how the body processes the drug. Researchers also looked at changes in liver fat and inflammation us…
Phase: PHASE1 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New cocktail of drugs shows promise for tough bile duct cancer
Disease control CompletedThis study tested a combination of three drugs—camrelizumab, apatinib, and chemotherapy (gemcitabine plus cisplatin)—in 49 people with advanced biliary tract cancer that could not be removed by surgery. The goal was to see if the combo is safe and how well it shrinks tumors. Resu…
Phase: PHASE1, PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Hearts from hepatitis c donors could save lives in organ shortage
Disease control CompletedThis study tests whether hearts from donors with hepatitis C can be safely transplanted into people without the virus. Twenty adults with end-stage heart failure on the transplant waiting list will receive these hearts and take antiviral medication to prevent infection. The goal …
Phase: PHASE2 • Sponsor: Mary E. Keebler, MD • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New combo therapy shows promise for rare sarcomas
Disease control CompletedThis study looked at adding the drug pazopanib to standard radiation or chemoradiation before surgery for patients with certain soft tissue sarcomas. The goal was to see if the combination is safe and helps shrink tumors more effectively. About 140 adults and children with newly …
Phase: PHASE2, PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Engineered immune cells take on liver cancer in early trial
Disease control CompletedThis early-phase trial tested a new approach for advanced liver cancer that has not responded to standard treatments. Researchers took participants' own immune cells, modified them in a lab to target a protein called AFP found on cancer cells, and infused them back after a short …
Phase: PHASE1 • Sponsor: Adaptimmune • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Smart tags and a phone app could boost hepatitis c treatment success
Disease control CompletedThis trial tests a smartphone app called Tappt that uses smart tags to help people with hepatitis C stick to their daily oral medication. Participants scan tags each time they take a dose, and the app tracks adherence. The study compares their results to historical data from simi…
Phase: NA • Sponsor: University of Illinois at Chicago • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug cocktail aims to stop liver cancer recurrence after surgery
Disease control CompletedThis study tested whether a combination of two drugs (atezolizumab and bevacizumab) can prevent liver cancer from returning in people who had surgery or ablation to remove their tumor. About 668 participants at high risk of recurrence were randomly assigned to receive the drug co…
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Modified virus injected into tumors shows promise for liver cancer
Disease control CompletedThis phase 2 trial tested a modified virus called JX-594 (Pexa-Vec) in 30 people with liver cancer that could not be surgically removed. The virus was injected directly into the liver tumors to see if it could stop the cancer from growing. Researchers measured how many patients h…
Phase: PHASE2 • Sponsor: Jennerex Biotherapeutics • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Can a blood pressure drug reverse liver damage in hepatitis c?
Disease control CompletedThis study tested whether adding prazosin, a drug usually used for high blood pressure, to standard hepatitis C treatment could reduce liver scarring. 112 adults with chronic hepatitis C (genotype 1 or 4) and severe liver fibrosis took part. Researchers measured changes in liver …
Phase: PHASE2 • Sponsor: French National Agency for Research on AIDS and Viral Hepatitis • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New hope for liver cancer patients with cirrhosis? tiny trial tests drug duo
Disease control CompletedThis small, completed phase II study tested the safety of combining two drugs—atezolizumab (an immunotherapy) and bevacizumab (a blood vessel blocker)—in 6 people with advanced liver cancer who also had moderate cirrhosis (Child-Pugh B7 or B8). The goal was to see if this treatme…
Phase: PHASE2 • Sponsor: Howard S Hochster • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New combo approach before surgery may improve outcomes for massive liver tumors
Disease control CompletedThis study looked at 715 patients with very large liver cancers (over 10 cm) to see if giving a combination of local treatments (like chemo directly into the liver) and body-wide treatments (targeted drugs and immunotherapy) before surgery helps them live longer. Patients were di…
Sponsor: Tongji Hospital • Aim: Disease control
Last updated Jun 27, 2026 13:08 UTC
-
New combo therapy aims to clear hepatitis b and d in 20-patient trial
Disease control CompletedThis early-stage study tested a new treatment approach for adults with chronic hepatitis B or D. Twenty participants received two medications in sequence: P1101 (a type of interferon) followed by an anti-PD1 drug. The main goal was to check safety and tolerability, while also loo…
Phase: PHASE1 • Sponsor: PharmaEssentia • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
Promising drug cocktail targets Hard-to-Treat liver cancer
Disease control CompletedThis study tested a combination of two drugs, cadonilimab and regorafenib, in 36 adults with advanced liver cancer that had worsened after standard treatments. The goal was to see if the combo could slow cancer growth and how safe it was. Results may help develop better options f…
Phase: PHASE1, PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New hope for tough hepatitis c cases: triple therapy shows promise
Disease control CompletedThis study tested a combination of three drugs—Grazoprevir/Elbasvir, Sofosbuvir, and Ribavirin—in 26 adults with hepatitis C genotype 1 or 4 who had not been cured by previous treatments. The goal was to see if 16 or 24 weeks of this therapy could clear the virus. The main measur…
Phase: PHASE2 • Sponsor: ANRS, Emerging Infectious Diseases • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
Virus therapy takes on liver cancer in major trial
Disease control CompletedThis study tested whether adding a virus-based immunotherapy (Pexa-Vec) to the standard drug sorafenib helps people with advanced liver cancer live longer. About 459 adults with advanced liver cancer who had not received prior treatment took part. The approach uses a modified vir…
Phase: PHASE3 • Sponsor: SillaJen, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
Experimental vaccine targets Hard-to-Treat cancers in first human test
Disease control CompletedThis early-phase trial tested a new type of vaccine made from a patient's own immune cells (dendritic cells) that are engineered to target a protein called WT1 found in many cancers. Ten people with advanced esophageal, pancreatic, ovarian, or liver cancer received six vaccines o…
Phase: PHASE1, PHASE2 • Sponsor: University Hospital, Antwerp • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
Blood donation may improve diabetes and fatty liver, study finds
Disease control CompletedThis study tested whether regularly removing blood (like donating blood) can lower iron levels and improve diabetes control and fatty liver disease. 132 adults aged 40-75 with prediabetes or diabetes took part. The treatment group gave blood several times, while the control group…
Phase: NA • Sponsor: Wake Forest University Health Sciences • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New drug MK-1200 tested in advanced cancer patients
Disease control CompletedThis study tested a new drug called MK-1200 in 13 people with advanced solid tumors, including stomach, esophageal, bile duct, and pancreatic cancers. The goal was to find safe doses and see if the drug could shrink tumors. The study is complete, but results are not yet available…
Phase: PHASE1, PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
Promising new treatment for rare liver disease shows potential in Late-Stage trial
Disease control CompletedThis study tested a drug called seladelpar in 96 adults with primary biliary cholangitis (PBC), a rare liver disease. Participants had not responded well or could not tolerate the standard treatment. The goal was to see if seladelpar could lower a key liver enzyme (alkaline phosp…
Phase: PHASE3 • Sponsor: Gilead Sciences • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
Could a flavonoid combo reverse liver scarring and prevent cancer in hepatitis b?
Disease control CompletedThis completed phase 4 trial tested whether adding SB Flavon (a blend of flavonoids, vitamin C, and L-arginine) to standard Tenofovir therapy can reverse advanced liver scarring (cirrhosis) and prevent liver cancer in 134 people with chronic hepatitis B. The study measured liver …
Phase: PHASE4 • Sponsor: Trieu, Nguyen Thi, M.D. • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
New hepatitis c drug combo shows promise in early trial
Disease control CompletedThis study tested whether a new form of interferon (IFN alfa-2b XL) combined with ribavirin works better and causes fewer side effects than the standard treatment for chronic hepatitis C (genotypes 1 or 4). 84 adults who had not been treated before or had not responded to previou…
Phase: PHASE2 • Sponsor: ANRS, Emerging Infectious Diseases • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
Diet plan may help fight muscle weakness in liver cirrhosis
Disease control CompletedLiver cirrhosis often causes muscle weakness and frailty, even in stable patients. This study tested whether a personalized diet with extra calories and protein, along with nutrition counseling, could improve muscle strength and quality of life. About 70 adults with stable cirrho…
Phase: NA • Sponsor: University of Roma La Sapienza • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New study tests better ways to link former inmates to HIV and addiction treatment
Disease control CompletedThis study tested two different approaches to help people recently released from jail or prison get connected to care for HIV, hepatitis C, STIs, and opioid use disorder. Over 600 adults took part. The goal was to see which method worked better for starting and staying on treatme…
Phase: NA • Sponsor: Yale University • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New drug combo shows promise in shrinking liver tumors before surgery
Disease control CompletedThis study tested a combination of two drugs (atezolizumab and bevacizumab) given before surgery to people with liver cancer. The goal was to see how well the drugs shrink the tumor and how they affect the immune system. 40 participants were enrolled, and researchers also studied…
Phase: PHASE2 • Sponsor: Tae Won Kim • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
New drug shows promise for alcohol hepatitis in early trial
Disease control CompletedThis study tested an experimental drug called ADX-629 in 4 adults with moderate alcohol-related hepatitis. The goal was to see if the drug is safe and can help control liver inflammation. Participants had to stop drinking alcohol during the trial. The study is now complete, and r…
Phase: PHASE2 • Sponsor: Aldeyra Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
New drug cocktail shows promise for tough bile duct cancer
Disease control CompletedThis trial tested a three-drug combination—chemotherapy infused into the liver, an immunotherapy drug (tislelizumab), and a targeted pill (regorafenib)—as a first treatment for 31 people with advanced bile duct cancer that couldn't be removed by surgery. The goal was to see how m…
Phase: PHASE2 • Sponsor: The First Affiliated Hospital of Zhengzhou University • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New drug shows promise in shrinking fatty liver
Disease control CompletedThis study tested a new medication called efinopegdutide in 124 adults with fatty liver disease (also called MASLD). The goal was to see if taking the drug every two weeks or every week could safely reduce liver fat. After 28 weeks, the drug helped lower liver fat, and researcher…
Phase: PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New drug shows promise for babies with rare liver disorders
Disease control CompletedThis study tested the safety of a drug called maralixibat in 27 infants under 12 months old with Alagille syndrome or progressive familial intrahepatic cholestasis (PFIC), two rare liver diseases that cause bile buildup. The drug is given as an oral solution and aims to reduce bi…
Phase: PHASE2 • Sponsor: Mirum Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New drug combo for liver cancer passes safety check in 1,200 patients
Disease control CompletedThis study looked at the safety of two drugs, IMJUDO and IMFINZI, given together or alone to 1,200 people with advanced liver cancer that cannot be removed by surgery. The main goal was to track any side effects that happen in everyday medical use. The study is now complete and h…
Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Diet showdown: mediterranean vs DASH for fatty liver
Disease control CompletedThis study tested whether Mediterranean or DASH diets improve liver function in people with nonalcoholic fatty liver disease (NAFLD). 75 adults with mild to moderate liver enzyme elevations were split into three groups: one following general dietary guidelines, one on a Mediterra…
Phase: NA • Sponsor: University of Lahore • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New drug HPG1860 shows promise in reducing liver fat in NASH patients
Disease control CompletedThis study tested three different doses of HPG1860, an experimental oral drug, against a placebo in 89 adults with nonalcoholic steatohepatitis (NASH), a type of fatty liver disease. The main goals were to check safety and see if the drug could lower liver fat content measured by…
Phase: PHASE2 • Sponsor: Hepagene (Shanghai) Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:39 UTC
-
New drug aims to tame hepatitis b in HIV patients
Disease control CompletedThis Phase 2 trial tested an oral drug called selgantolimod in 29 adults with both chronic hepatitis B and HIV. Participants had been on stable antiviral therapy for both viruses for at least 5 years. The study aimed to see if the drug is safe and can lower hepatitis B surface an…
Phase: PHASE2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
Antibiotics before endoscopy: necessary or not for cirrhosis patients?
Disease control CompletedThis study looked at whether giving antibiotics before an endoscopic procedure helps prevent fever and rebleeding in people with cirrhosis who have had variceal bleeding before. 226 patients were randomly assigned to receive the antibiotic ceftriaxone or no antibiotics before the…
Phase: NA • Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New drug cocktail may make inoperable liver cancer removable
Disease control CompletedThis study tested a combination of chemotherapy infused into the liver artery plus two drugs (camrelizumab and apatinib) in 21 people with liver cancer that could not be surgically removed. The goal was to shrink the tumors enough to allow surgery. The study is complete, and resu…
Phase: PHASE2 • Sponsor: Shandong Cancer Hospital and Institute • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
HIV-Positive livers safe for HIV-Positive patients? landmark trial results
Disease control CompletedThis study looked at whether it is safe to transplant livers from deceased HIV-positive donors into HIV-positive recipients. Researchers followed 80 participants to track complications like graft failure, infections, and HIV breakthrough. The goal was to see if using HIV-positive…
Phase: NA • Sponsor: Johns Hopkins University • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
Experimental combo targets Hard-to-Treat GI cancers
Disease control CompletedThis early-phase trial tested two drugs together—pembrolizumab (Keytruda) and XL888—in 47 people with advanced gastrointestinal cancers like colorectal and pancreatic cancer that had spread or could not be removed. The main goal was to find the safest dose and check for side effe…
Phase: PHASE1 • Sponsor: Emory University • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
Zapping tumors with precision radiation may help control limited metastatic breast cancer
Disease control CompletedThis study looked at whether adding focused radiation (SBRT) or surgery to standard treatments like chemo or hormone therapy helps people with breast cancer that has spread to just one or two places. 129 participants were randomly assigned to get standard care alone or standard c…
Phase: PHASE2, PHASE3 • Sponsor: NRG Oncology • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
Immunotherapy cocktail before surgery shows promise against tough cancers
Disease control CompletedThis study tested whether adding an experimental drug (CCR2/5-inhibitor or anti-IL-8) to the immunotherapy nivolumab before and after surgery could help shrink tumors and improve long-term survival in people with non-small cell lung cancer or liver cancer. 48 participants receive…
Phase: PHASE2 • Sponsor: Icahn School of Medicine at Mount Sinai • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
Virus injection targets liver tumors in early trial
Disease control CompletedThis early-phase study tested a new treatment called JX-594, a modified virus injected directly into liver tumors. The goal was to find the safest dose and see if it could shrink tumors in 14 patients with advanced liver cancer that had not responded to standard treatments. The s…
Phase: PHASE1 • Sponsor: Jennerex Biotherapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New shot shows promise against fatty liver disease
Disease control CompletedThis study tested a weekly injection called pemvidutide in 212 adults with NASH, a serious liver condition linked to fat buildup. The goal was to see if the drug could reduce liver fat and scarring without worsening the disease. Participants received either the drug or a placebo …
Phase: PHASE2 • Sponsor: Altimmune, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New drug aims to cure hepatitis b without lifelong pills
Disease control CompletedThis Phase 3 trial tests a drug called bepirovirsen in nearly 1,000 adults with chronic hepatitis B who are already on standard antiviral therapy. The goal is to see if bepirovirsen can suppress the virus enough that participants can safely stop all hepatitis B medications and re…
Phase: PHASE3 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
Promising combo therapy for incurable liver cancer shows potential in phase 3 trial
Disease control CompletedThis study tested whether adding two drugs (lenvatinib and pembrolizumab) to a standard liver cancer treatment called TACE helps people with liver cancer that cannot be removed by surgery. About 479 participants received either the drug combo plus TACE or TACE alone. The goal was…
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New combo therapy shows promise in controlling advanced liver cancer
Disease control CompletedThis study tested a combination of Y90 radioembolization (a targeted radiation treatment for the liver) and nivolumab (an immunotherapy drug) in 40 Asian patients with advanced liver cancer that could not be surgically removed. The goal was to see if the combination could shrink …
Phase: PHASE2 • Sponsor: National Cancer Centre, Singapore • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
Second chance: new combo tackles hepatitis c in HIV patients
Disease control CompletedThis study tested a combination of peginterferon alfa2a and ribavirin in 17 HIV-positive people with chronic hepatitis C who had not responded to earlier treatment. Participants received weekly injections and daily pills for 48 weeks. The main goal was to see if the virus became …
Phase: PHASE2 • Sponsor: University Hospital, Bordeaux • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New drug cocktail aims to fight advanced cancers
Disease control CompletedThis early-phase study tested a daily combination of two oral drugs, axitinib and everolimus, in 19 people with advanced solid tumors, particularly kidney cancer. The main goal was to find the safest dose by monitoring side effects in the first month. Researchers also tracked how…
Phase: PHASE1 • Sponsor: University Hospital, Bordeaux • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New drug aims to free hepatitis b patients from daily pills
Disease control CompletedThis Phase 3 study tests bepirovirsen, an experimental drug, in 857 adults with chronic hepatitis B who are already on standard antiviral therapy. The goal is to see if bepirovirsen can suppress the virus enough to allow patients to stop all hepatitis B treatments and remain viru…
Phase: PHASE3 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
Radioactive beads show promise for liver tumors in french registry
Disease control CompletedThis completed registry tracked 332 liver cancer patients in France who received SIR-Spheres, tiny radioactive beads injected into the liver's blood supply to target tumors. The goal was to see how this treatment is used in everyday practice and to monitor safety and survival. Re…
Sponsor: Cardiovascular and Interventional Radiological Society of Europe • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
Can vitamin e tame fatty liver? new study tests the right dose
Disease control CompletedThis study tested different doses of vitamin E in 200 adults with nonalcoholic fatty liver disease (NAFLD) to find the best dose for improving liver health. Participants took vitamin E or a placebo for 24 weeks, and researchers measured changes in a key liver enzyme (ALT). The go…
Phase: PHASE2 • Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
Could a triple therapy beat back tough liver cancer?
Disease control CompletedThis completed study tested whether adding a liver-directed chemotherapy infusion (HAIC) to standard immunotherapy and anti-angiogenesis drugs improves outcomes for people with advanced liver cancer that has spread into the portal vein. Over 1,600 participants were included. The …
Sponsor: Zhongda Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
New combo therapy shows promise for tough liver cancer cases
Disease control CompletedThis study looked at adding a procedure called TACE (which blocks blood flow to tumors) to a mix of immunotherapy and anti-angiogenesis drugs for people with advanced liver cancer that has invaded major blood vessels. Over 2,600 participants were included to see if the triple com…
Sponsor: Zhongda Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
Yeast vaccine shows promise in stopping Cancer's return
Disease control CompletedThis early-stage study tested a custom-made yeast vaccine designed to train the immune system to recognize and attack leftover cancer cells. Five adults with various cancers (like colorectal, breast, or lung) who had completed initial treatment received the vaccine. The goal was …
Phase: PHASE1 • Sponsor: NantBioScience, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
New drug combo shows early promise against Hard-to-Treat cancers
Disease control CompletedThis early-stage study tested a new drug called BI 765049, alone or combined with another drug (ezabenlimab), in 21 Asian adults with advanced solid tumors (stomach, colorectal, pancreatic, liver, head and neck, or lung cancer) that have a specific marker called B7-H6. The main g…
Phase: PHASE1 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
Natural supplement shows promise for fatty liver
Disease control CompletedThis study tested whether taking phytosterols (plant-based supplements) for 3 months can improve liver health, cholesterol, and insulin levels in people with nonalcoholic fatty liver disease (NAFLD). 27 participants took either phytosterol pills or a placebo. Researchers measured…
Phase: NA • Sponsor: University of Jordan • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
New injection aims to tame chronic hepatitis b
Disease control CompletedThis study tests an experimental drug called AHB-137 in healthy volunteers and people with chronic hepatitis B who are already on antiviral medication. The goal is to check if the drug is safe and shows early signs of controlling the virus. About 129 participants will receive eit…
Phase: PHASE1, PHASE2 • Sponsor: Ausper Biopharma Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
New drug shows promise in early liver cancer trial
Disease control CompletedThis early-phase study tested a drug called itacitinib in 19 adults with advanced liver cancer that had not responded to first-line treatment. The goal was to check the drug's safety and see if it could shrink tumors or slow cancer growth. Itacitinib works by blocking a protein t…
Phase: PHASE1 • Sponsor: Imperial College London • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Which ketogenic diet works best? new study compares meal replacements vs. natural foods
Disease control CompletedThis study looked at how well adults with obesity or complicated overweight could stick to different very low-calorie ketogenic diets (VLCKD) in a real-world clinic. Participants chose one of four diet plans, ranging from all-natural foods to all meal replacements, and followed a…
Sponsor: University of Bologna • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
One-Stop care: hepatitis c treatment may curb HIV and opioid risks
Disease control CompletedThis study tested a new way to care for people who inject drugs and have hepatitis C. Along with standard hepatitis C treatment, participants were offered HIV prevention medication and buprenorphine for opioid use disorder. The goal was to see if this combined approach could cure…
Sponsor: University of Maryland, Baltimore • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New combo shows promise for Hard-to-Treat cancers
Disease control CompletedThis study tested a combination of two drugs, lenvatinib and pembrolizumab, in 611 people with advanced cancers like breast, ovarian, stomach, colorectal, brain, bile duct, or pancreatic cancer that had stopped responding to standard treatments. The goal was to see if the combo c…
Phase: PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New drug DD01 shows promise for fatty liver in early trial
Disease control CompletedThis Phase 2 trial tested a drug called DD01 in 67 overweight or obese adults with a type of fatty liver disease (MASLD/MASH). The goal was to see if DD01 could safely reduce liver fat by at least 30% over 48 weeks compared to a placebo. The study is completed, and results will s…
Phase: PHASE2 • Sponsor: Neuraly, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
Tiny trial hopes drug can ease liver damage in rare triple condition
Disease control CompletedThis completed phase 2 trial tested a drug called foscenvivint in just 5 people with liver cirrhosis caused by HIV and hepatitis C co-infection who also have hemophilia. The goal was to see if the drug could improve liver function scores over 24 weeks. Because the study is very s…
Phase: PHASE2 • Sponsor: Kiminori Kimura, MD • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
Radiation may buy time for liver cancer patients before stronger meds needed
Disease control CompletedThis study tested whether giving radiotherapy to liver cancer patients with limited tumor growth (oligo progression) could delay the need for second-line drug therapy. Thirty-six adults with advanced hepatocellular carcinoma received targeted radiation. The goal was to see if thi…
Sponsor: Shandong Cancer Hospital and Institute • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
Experimental drug PRL3-ZUMAB shows promise in Hard-to-Treat cancers
Disease control CompletedThis study tested a new drug called PRL3-ZUMAB in 14 people with advanced solid tumors (like stomach or liver cancer) that stopped responding to standard treatments. The drug was given every two weeks to see if it could shrink tumors or stop them from growing. Researchers also lo…
Phase: PHASE2 • Sponsor: National Cancer Centre, Singapore • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
New pill combo aims to tame hepatitis d in small trial
Disease control CompletedThis completed Phase 3 trial tested a once-daily combination of two drugs, lonafarnib and ritonavir, in 10 adults with chronic hepatitis D. The goal was to see if the regimen is safe and can lower the amount of virus in the blood over 48 weeks of treatment and 24 weeks of follow-…
Phase: PHASE3 • Sponsor: Soroka University Medical Center • Aim: Disease control
Last updated Jun 27, 2026 12:26 UTC
-
New vaccine combo aims to tame chronic hepatitis b
Disease control CompletedThis phase 2b trial tested a combination of two experimental vaccines (VTP-300) plus a low dose of the cancer drug nivolumab in 121 adults with chronic hepatitis B who were already on antiviral medication. The goal was to see if the treatment could significantly lower hepatitis B…
Phase: PHASE2 • Sponsor: Barinthus Biotherapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:26 UTC
-
Could a weekly shot tackle fatty liver and obesity?
Disease control CompletedThis study tests a medicine called survodutide in adults with overweight or obesity and a liver condition called NASH. Participants receive weekly injections of survodutide or a placebo for about a year, along with diet and exercise advice. The goal is to see if the drug reduces …
Phase: PHASE3 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jun 27, 2026 12:26 UTC
-
Promising long-term results for rare liver disease drug in kids
Disease control CompletedThis study looked at the long-term safety and effectiveness of a drug called A4250 (odevixibat) in 116 children with progressive familial intrahepatic cholestasis (PFIC), a rare liver disease. The children took the drug for up to 72 weeks. The study measured changes in bile acid …
Phase: PHASE3 • Sponsor: Albireo, an Ipsen Company • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
Hepatitis c donor livers safely transplanted into healthy recipients
Disease control CompletedThis study tested whether livers from donors with hepatitis C could be safely transplanted into people without hepatitis C. Five patients on the liver transplant waiting list received these livers and were then treated with an antiviral drug to prevent infection. The goal was to …
Phase: PHASE2 • Sponsor: Fernanda P Silveira, MD, MS • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
New drug shows promise for rare liver disease in Late-Stage trial
Disease control CompletedThis study tested a drug called saroglitazar magnesium in 196 adults with primary biliary cholangitis (PBC), a chronic liver disease. Participants either took the drug or a placebo to see if it improved liver function markers. The goal was to lower certain liver enzymes and bilir…
Phase: PHASE2, PHASE3 • Sponsor: Zydus Therapeutics Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
New combo aims to free hepatitis b patients from daily pills
Disease control CompletedThis Phase 2 study tested an experimental drug called AB-729 combined with pegylated interferon and standard antiviral pills in 43 adults with chronic hepatitis B. The goal was to see if this approach could safely lower hepatitis B surface antigen levels and allow some participan…
Phase: PHASE2 • Sponsor: Arbutus Biopharma Corporation • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
Which antibiotic wins for liver infection? new study compares ciprofloxacin and ceftriaxone
Disease control CompletedThis study compared two antibiotics—ciprofloxacin and ceftriaxone—given intravenously to 310 patients with liver cirrhosis who developed a serious infection called spontaneous bacterial peritonitis. The goal was to see which drug better controlled fever, abdominal pain, and infec…
Phase: NA • Sponsor: Shahida Islam Medical Complex • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
Home liver fat tracker helps fight fatty liver
Disease control CompletedThis study tested whether a device that measures liver fat at home can motivate people with non-alcoholic fatty liver disease (NAFLD) to stick with diet and exercise. Ten adults with NAFLD used the device and received standard care. The goal was to see if home monitoring leads to…
Phase: NA • Sponsor: The University of Hong Kong • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
Keytruda may keep liver cancer at bay after surgery
Disease control CompletedThis large phase 3 trial tested whether the immunotherapy drug pembrolizumab (Keytruda) can prevent liver cancer from coming back in people who had successful surgery or ablation. 959 participants received either pembrolizumab or a placebo every three weeks. The study measured ho…
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Could a common supplement help fatty liver disease?
Disease control CompletedThis early-phase study tested an oral drug called idebenone in 53 adults with non-alcoholic steatohepatitis (NASH) and mild-to-moderate liver scarring. The main goal was to check safety and tolerability, while also looking for signs that the drug might reduce liver stiffness and …
Phase: PHASE1, PHASE2 • Sponsor: Stanford University • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New combo therapy shows promise for tough-to-treat liver cancer
Disease control CompletedThis study tested a combination of proton beam radiotherapy followed by two drugs (Tecentriq and Avastin) in 63 adults with advanced liver cancer that had spread into the portal vein. The goal was to see if this approach could help control the cancer and improve survival. Partici…
Phase: PHASE2 • Sponsor: Samsung Medical Center • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New drug targets tough childhood cancers with genetic flaws
Disease control CompletedThis phase 2 trial tested the drug samotolisib in 18 children and young adults with advanced solid tumors, non-Hodgkin lymphoma, or histiocytic disorders that had spread, returned, or stopped responding to treatment. Only patients whose tumors had specific mutations in the TSC or…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New hope for hepatitis b: experimental combo aims to clear the virus
Disease control CompletedThis study tested whether combining two experimental drugs (VIR-2218 and VIR-3434) with or without a standard immune booster (PEG-IFNα) can safely eliminate hepatitis B surface antigen in people with chronic hepatitis B. 244 adults with long-term infection who were already on ant…
Phase: PHASE2 • Sponsor: Vir Biotechnology, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Radiation zaps liver tumors in patients too sick for surgery
Disease control CompletedThis pilot study tested a precise type of radiation called stereotactic body radiation therapy (SBRT) in 20 adults with liver cancer that could not be surgically removed. The goal was to see if the treatment is safe and to measure how long patients survive. The approach aims to d…
Phase: NA • Sponsor: Montefiore Medical Center • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
Can a tailored mediterranean diet and exercise reverse fatty liver?
Disease control CompletedThis study tested two versions of a low-calorie Mediterranean diet, each with different carb and fat levels, combined with moderate aerobic exercise in 36 adults with obesity and fatty liver disease (NAFLD). The goal was to see if one diet plan worked better than the other at red…
Phase: NA • Sponsor: Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
Triple therapy shows promise for advanced liver cancer
Disease control CompletedThis study tested a triple combination treatment for advanced liver cancer that has spread. It combines a procedure called TACE (which blocks blood flow to the tumor) with immunotherapy drugs (PD-1/PD-L1 inhibitors) and targeted therapies (VEGF-TKI or bevacizumab). The goal is to…
Sponsor: Zhongda Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
Triple therapy shows promise for intermediate liver cancer
Disease control CompletedThis study tested a three-pronged approach for intermediate-stage liver cancer: a procedure that blocks blood flow to the tumor (TACE), immunotherapy drugs that help the immune system fight cancer, and targeted drugs that stop blood vessel growth. Over 900 patients participated. …
Sponsor: Zhongda Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
Liver cancer patients get new hope: study tests two drug cocktails after first treatment fails
Disease control CompletedThis study looked at 200 people with advanced liver cancer whose first treatment (bevacizumab plus sintilimab) stopped working. Researchers compared two second-line options: a PD-1 inhibitor combined with either lenvatinib or regorafenib. The goal was to see which combo works bet…
Phase: NA • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
New combo therapy shows promise for tough liver cancer cases
Disease control CompletedThis study tested a new treatment for advanced liver cancer that has spread into the major blood vessels of the liver. Thirty patients received a special type of radiation along with an immunotherapy drug called tislelizumab. The goal was to see if this combination could help pat…
Phase: PHASE2 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
Tomato diet shows promise for fatty liver relief
Disease control CompletedThis study looked at whether a diet rich in tomatoes could improve liver health, gut function, and blood sugar in people with non-alcoholic fatty liver disease (NAFLD). Eighty participants either ate a tomato-free diet or one with added tomatoes and sauce for six weeks. Researche…
Phase: NA • Sponsor: Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Can a Two-Drug cocktail reverse liver scarring? early trial hints at possibility
Disease control CompletedThis study tested whether a combination of two drugs, dasatinib and quercetin, can reduce liver scarring in people with non-alcoholic fatty liver disease (NAFLD) and fibrosis. Thirty adults with biopsy-confirmed liver scarring took either the drug combo or a placebo in cycles ove…
Phase: PHASE1, PHASE2 • Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
New hope for hepatitis b: experimental drug shows promise in mid-stage trial
Disease control CompletedThis study tested an experimental drug called VIR-2218 in 84 adults with chronic hepatitis B. Some participants received VIR-2218 alone, and others got it combined with pegylated interferon. The main goals were to check safety and how well the drug works against the virus. The st…
Phase: PHASE2 • Sponsor: Vir Biotechnology, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Immunotherapy drug shows promise in bile duct cancer trial
Disease control CompletedThis Phase 3 trial tested whether adding the immunotherapy drug pembrolizumab to standard chemotherapy (gemcitabine and cisplatin) helps people with advanced bile duct cancer live longer. The study enrolled 158 Chinese adults with cancer that had spread or could not be removed by…
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Dietary tweak shows promise for fatty liver management
Disease control CompletedThis study looked at whether changing the amount of methyl donor nutrients (like folate and choline) in the diet could help people with non-alcoholic fatty liver disease (NAFLD). The goal was to reduce liver fat and improve liver function. 51 participants completed the study, and…
Phase: NA • Sponsor: Fu Jen Catholic University Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
Prehab before liver transplant: a new hope for frail patients?
Disease control CompletedThis study tested whether a structured program combining exercise, nutritional advice, and psychological support is safe and doable for frail adults with cirrhosis waiting for a liver transplant. Twenty-five participants were enrolled to see if they could stick with the program a…
Phase: NA • Sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
Rice bran shows promise for fatty liver in small study
Disease control CompletedThis study looked at whether adding rice bran to nutrition education helps people with fatty liver disease. 58 overweight or obese adults with moderate fatty liver were split into two groups: one got nutrition education alone, the other got nutrition education plus rice bran. Res…
Phase: NA • Sponsor: Shih Chien University • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
New hope for kids with Hard-to-Treat cancers: targeted drug shows promise
Disease control CompletedThis study tested a drug called tazemetostat in 20 children whose cancers had come back or weren't responding to treatment. The children had specific gene changes (EZH2, SMARCB1, or SMARCA4) in their tumors. The goal was to see if the drug could shrink or slow the growth of these…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
Quick HCV treatment with peer support boosts cure rates for drug users
Disease control CompletedThis study tested whether offering rapid hepatitis C treatment with help from a peer mentor (someone who has been cured) works better than the usual referral to an outside clinic. 198 people who use drugs and were in an opioid treatment program took part. The goal was to see if m…
Phase: NA • Sponsor: Johns Hopkins University • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
Blood pressure drug may halt liver damage in hep c patients
Disease control CompletedThis study tested whether irbesartan, a blood pressure medication, can slow the progression of liver scarring (fibrosis) in adults with chronic hepatitis C who cannot take or did not respond to antiviral therapy. Over two years, 166 participants took either irbesartan or a placeb…
Phase: PHASE3 • Sponsor: ANRS, Emerging Infectious Diseases • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
Double antenna ablation shows promise for small liver tumors
Disease control CompletedThis study tested a new way to destroy small liver tumors using two microwave antennas at once, compared to the standard single antenna method. Twenty patients with small hepatocellular carcinoma (liver cancer) were treated. The goal was to see if the two-antenna approach could m…
Phase: NA • Sponsor: Seoul National University Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
New pill aims to tame chronic hepatitis b
Disease control CompletedThis early-stage trial tests AB-101, an oral drug that blocks a protein called PD-L1 to help the immune system fight the hepatitis B virus. The study involves 128 people, including healthy volunteers and patients with chronic hepatitis B. Researchers are primarily checking for sa…
Phase: PHASE1 • Sponsor: Arbutus Biopharma Corporation • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
New hope: hepatitis c drugs after liver cancer treatment
Disease control CompletedThis study tested whether interferon-free drug combinations can cure hepatitis C in 150 people who had been successfully treated for liver cancer. Participants took pills like sofosbuvir and ribavirin for 12 weeks. The main goal was to see if the virus stayed undetectable 12 week…
Phase: PHASE3 • Sponsor: National Hepatology & Tropical Medicine Research Institute • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
New needle combo zaps returning liver tumors after failed chemo
Disease control CompletedThis study tested a special type of radiofrequency ablation using two cooled needles that also release saline to treat liver cancer that came back after chemoembolization. The goal was to see if this technique could better destroy the tumor and prevent it from growing back. One h…
Phase: NA • Sponsor: Seoul National University Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
New chemo cocktail shows promise against tough bile duct cancer
Disease control CompletedThis study tested two different chemotherapy drug combinations in 92 people with advanced bile duct or gallbladder cancer that could not be removed by surgery. The goal was to see which combination better kept the cancer from growing for at least 6 months. Participants received e…
Phase: PHASE2 • Sponsor: National Health Research Institutes, Taiwan • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
New triple therapy aims to clear hepatitis c before liver transplant
Disease control CompletedThis study tested a combination of three drugs (pegylated interferon, ribavirin, and boceprevir) in 58 adults with genotype 1 hepatitis C and cirrhosis who were waiting for a liver transplant. The goal was to see if the treatment could clear the virus before surgery. The study me…
Phase: PHASE2 • Sponsor: French National Agency for Research on AIDS and Viral Hepatitis • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
New hope for HIV patients with Hard-to-Treat hepatitis c
Disease control CompletedThis study tested a more intensive hepatitis C treatment in 58 adults who have both HIV and hepatitis C (genotypes 1 or 4) and had not responded to previous therapy. Participants received higher doses of two drugs, peginterferon alfa-2a and ribavirin, for up to 18 months. The goa…
Phase: PHASE2 • Sponsor: ANRS, Emerging Infectious Diseases • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
HIV patients with liver failure get new drug combo tested in transplant study
Disease control CompletedThis study looked at how the HIV drug raltegravir works in people with severe liver disease who need a liver transplant. It included 14 HIV-positive adults with end-stage liver failure. Researchers checked how the drug behaves in the body and how it interacts with anti-rejection …
Phase: PHASE1, PHASE2 • Sponsor: ANRS, Emerging Infectious Diseases • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Diabetes pills may fight fatty liver, study finds
Disease control CompletedThis study looked at whether a class of diabetes drugs called SGLT2 inhibitors can improve fatty liver disease in people with type 2 diabetes. 150 adults took the drugs for 6 months, and researchers measured changes in liver stiffness, fat levels, and blood sugar control. The goa…
Phase: PHASE3 • Sponsor: Sohag University • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Can vitamin d boost hepatitis c treatment in tough cases?
Disease control CompletedThis study looked at whether adding vitamin D to standard hepatitis C treatment could help patients with genotype 1 or 4 who had not responded to previous therapy. 32 adults with low vitamin D levels were enrolled. The goal was to see if vitamin D could make the antiviral drugs w…
Phase: PHASE2 • Sponsor: French National Agency for Research on AIDS and Viral Hepatitis • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New hepatitis b drug shows early promise in small trial
Disease control CompletedThis early-stage trial tested an experimental injection called HH-006 in 36 adults with untreated chronic hepatitis B. The study aimed to check the drug's safety, how the body processes it, and whether it can lower virus levels. Participants received either HH-006 or a placebo ov…
Phase: PHASE1 • Sponsor: Huahui Health • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New hope for bile duct cancer: triple therapy shows promise after chemo fails
Disease control CompletedThis Phase 2 trial tested a combination of three treatments—local chemotherapy delivered via beads into the liver, a targeted drug called apatinib, and an immunotherapy (PD-1 antibody)—in 20 patients with advanced bile duct cancer that had worsened after standard first-line chemo…
Phase: PHASE2 • Sponsor: Sichuan Cancer Hospital and Research Institute • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New combo therapy shows promise for Hard-to-Treat cancers
Disease control CompletedThis study tested an experimental drug called BMS-986016 (anti-LAG-3) alone or combined with nivolumab in people with advanced solid tumors that had spread or couldn't be removed by surgery. It included several cancer types like lung, stomach, liver, kidney, bladder, head and nec…
Phase: PHASE1, PHASE2 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Targeted drug shows promise for kids with tough cancers
Disease control CompletedThis study tested a drug called palbociclib in 23 children and young adults (ages 1–21) whose cancers had come back or didn't respond to treatment. The drug works by blocking proteins that help cancer cells grow. The goal was to see if it could shrink tumors or slow the disease i…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New hope for Hard-to-Treat cancers? utidelone trial underway
Disease control CompletedThis phase 2 trial tests the drug utidelone in 126 people with advanced solid tumors (excluding breast, lung, and colorectal cancers) that have not responded to standard treatments. The study aims to see if the drug can shrink tumors and how safe it is. Participants receive utide…
Phase: PHASE2 • Sponsor: Beijing Biostar Pharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
Radioactive oil injection may keep liver cancer at bay
Disease control CompletedThis phase 3 trial tested whether a single injection of radioactive lipiodol (Lipiocis) into the liver artery could prevent hepatocellular carcinoma from coming back after surgery or ablation. The study enrolled 73 adults with cirrhosis and one or two liver tumors that had been s…
Phase: PHASE3 • Sponsor: ANRS, Emerging Infectious Diseases • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
New infusion drug targets MASH cirrhosis in small safety trial
Disease control CompletedThis study tested a drug called BI 770371 in 28 people with compensated cirrhosis caused by MASH, a liver disease linked to metabolism. Participants received either the drug or a placebo as an infusion every 3 weeks for 12 weeks. The main goal was to see how well the drug is tole…
Phase: PHASE2 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
Could stem cells offer a lifeline for End-Stage liver disease?
Disease control CompletedThis study tested whether umbilical cord stem cells given through a vein could help people with end-stage liver disease. Twenty-two adults received different doses to see if it improved survival and liver function. The goal was to find a safer, more accessible alternative to live…
Phase: NA • Sponsor: General Hospital of Shenyang Military Region • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
DNA vaccine could help hepatitis b patients stop daily pills
Disease control CompletedThis study tests whether a DNA vaccine can help people with chronic hepatitis B control the virus after they stop taking standard antiviral drugs. The vaccine aims to boost the immune system to delay the virus from becoming active again. The trial involves 70 adults who have unde…
Phase: PHASE1, PHASE2 • Sponsor: French National Agency for Research on AIDS and Viral Hepatitis • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
New hope for HIV patients with Hard-to-Treat hepatitis c
Disease control CompletedThis phase 2 study tested a combination of three drugs—telaprevir, peginterferon, and ribavirin—in 70 adults with both HIV and hepatitis C who had not been helped by standard treatment before. The goal was to see if this triple therapy could clear the hepatitis C virus from the b…
Phase: PHASE2 • Sponsor: ANRS, Emerging Infectious Diseases • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
Surgeons test wrapping trick to prevent pancreatic leaks after whipple
Disease control CompletedThis study tested a new way to reconnect the pancreas to the intestine during Whipple surgery for certain cancers. The new method uses a stent and wraps the connection with omentum (fatty tissue) to try to prevent leaks. 48 patients were split into two groups to compare the new t…
Phase: NA • Sponsor: Theodor Bilharz Research Institute • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
Stem cells show promise for failing livers
Disease control CompletedThis study tested whether multiple infusions of stem cells from donated umbilical cords could help people with end-stage liver disease. 92 adults received the stem cells through a vein, and researchers tracked liver function and complications. The goal was to see if repeated dose…
Phase: NA • Sponsor: General Hospital of Shenyang Military Region • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
Experimental drug BAT8010 tested in patients with advanced cancers
Disease control CompletedThis early-phase trial tested an experimental drug called BAT8010 in 23 people with advanced or metastatic solid tumors who had no other standard treatment options. The main goals were to check safety, find the best dose, and see if the drug shows any sign of shrinking tumors. Pa…
Phase: PHASE1 • Sponsor: Bio-Thera Solutions • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
Double attack on liver cancer: does adding RFA to TACE improve survival?
Disease control CompletedThis phase 3 trial tested whether adding radiofrequency ablation (RFA) to standard transarterial chemoembolization (TACE) improves outcomes for people with intermediate-stage liver cancer. 241 participants with 2-10 liver tumors were randomly assigned to receive either TACE alone…
Phase: PHASE3 • Sponsor: Ming Zhao • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
New pill shows promise against advanced cancers in early trial
Disease control CompletedThis study tested a new cancer drug called brigimadlin (BI 907828) in 266 adults with advanced solid tumors that had spread or stopped responding to standard treatments. The goal was to find a safe dose and see if the drug could shrink tumors. Brigimadlin is an MDM2 inhibitor tak…
Phase: PHASE1 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
Robotic surgery spares nerves to cut digestive woes in cirrhosis
Disease control CompletedThis study tested a new robotic surgery technique that protects the vagus nerve during spleen removal and blood vessel disconnection in 60 cirrhosis patients with portal hypertension. The goal was to see if it reduces common side effects like diarrhea and delayed stomach emptying…
Phase: NA • Sponsor: Northern Jiangsu People's Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
New drug combo shows promise in shrinking liver tumors before surgery
Disease control CompletedThis phase II trial tested whether giving the immunotherapy drug tislelizumab, alone or combined with the targeted therapy lenvatinib, before surgery could help shrink liver tumors in 36 patients with resectable hepatocellular carcinoma. The main goal was to see if at least half …
Phase: PHASE2 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
New blood test could save lives in liver failure bleeding emergencies
Disease control CompletedThis study tested whether a special blood test (ROTEM) can better guide blood transfusions in people with acute-on-chronic liver failure who are bleeding from enlarged veins. 262 participants were randomly assigned to receive transfusions based on either the new test or standard …
Phase: NA • Sponsor: Post Graduate Institute of Medical Education and Research, Chandigarh • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
Poop pills? fecal transplants tested for liver disease
Disease control CompletedThis completed Phase 3 trial tested whether fecal microbiota transplantation (FMT) could help people with liver cirrhosis. Nineteen patients received FMT via colonoscopy. Researchers measured liver stiffness and signs of brain confusion (hepatic encephalopathy) one month later. T…
Phase: PHASE3 • Sponsor: Cristian Ichim • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
New antibody shows promise against rare liver infection
Disease control CompletedThis study tested an experimental drug called HH-003 in 101 adults with chronic hepatitis delta, a serious liver disease. HH-003 is an antibody that targets hepatitis B virus, which is needed for hepatitis delta to survive. Participants received either a low or high dose of HH-00…
Phase: PHASE2 • Sponsor: Huahui Health • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
EPP drug levels under the microscope: afamelanotide study completed
Disease control CompletedThis study looked at how the drug afamelanotide (Scenesse) behaves in the bodies of 28 people with erythropoietic protoporphyria (EPP), a rare condition that causes severe pain on sun exposure. Researchers measured the drug's concentration in the blood after a single implant. The…
Phase: PHASE1, PHASE2 • Sponsor: Clinuvel Europe Limited • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Precision radiation zaps untreatable liver tumors in tiny pilot study
Disease control CompletedThis study tested a procedure called selective internal radiation therapy (SIRT) using Y-90 resin microspheres (SIR-Spheres) in one patient with liver cancer that could not be removed by surgery. The goal was to see if a flexible dosing approach could improve outcomes like tumor …
Sponsor: Methodist Health System • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Orange you glad you ate that? study tests fruit against fatty liver
Disease control CompletedThis study looked at whether eating 400 grams of fresh oranges daily for a month could improve metabolism in 60 adults with metabolic-associated fatty liver disease (MAFLD). Participants either ate oranges or other fruits. Researchers measured changes in liver fat and blood fats.…
Phase: NA • Sponsor: Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Immunotherapy combo shows promise for tough bile duct cancer
Disease control CompletedThis study tested whether adding the immunotherapy drug pembrolizumab to standard chemotherapy (gemcitabine/cisplatin) helps people with advanced bile duct or gallbladder cancer live longer. Over 1,000 participants received either the combination or chemo plus a placebo. The goal…
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Immunotherapy-Ablation combo shows promise in early liver cancer trial
Disease control CompletedThis study tested whether giving the immunotherapy drug pembrolizumab before and after a standard tumor-destroying procedure (ablation) could improve outcomes for 30 people with early-stage liver cancer. The goal was to see if the combination could shrink tumors and delay recurre…
Phase: PHASE2 • Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New combo therapy shows promise in liver cancer battle
Disease control CompletedThis study tested a new combination of two drugs (IBI310 and sintilimab) against the standard drug sorafenib for people with advanced liver cancer who had not received prior treatment. The goal was to see if the combination could help patients live longer or shrink tumors more ef…
Phase: PHASE3 • Sponsor: Innovent Biologics (Suzhou) Co. Ltd. • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
Mediterranean diet shows promise in fighting fatty liver
Disease control CompletedThis study looked at whether a Mediterranean diet, with or without added exercise, could help people with a type of fatty liver disease called MASLD. The goal was to see if the diet could reduce fat and scarring in the liver. 96 adults took part, and researchers used special MRI …
Phase: NA • Sponsor: Fundación Pública Andaluza para la gestión de la Investigación en Sevilla • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
New hope for advanced gut cancers? early trial tests targeted antibody
Disease control CompletedThis early-stage study tested a new drug called cabotamig in 33 adults with advanced cancers of the digestive system (like colon, pancreas, or liver) that had stopped responding to standard treatments. The goal was to see if the drug is safe and how it affects the body and tumors…
Phase: PHASE1 • Sponsor: Arbele Pty Ltd • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
New combo tackles tough liver cancer in tiny trial
Disease control CompletedThis small pilot study tested a combination of two drugs, alectinib and nivolumab, in 5 adults with advanced liver cancer that had not responded to standard treatments. The goal was to see if the combination could shrink tumors. Because it was a very early phase 1 trial with very…
Phase: PHASE1 • Sponsor: China Medical University Hospital • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
Bangkok project tests Same-Day hepatitis c care in community centers
Disease control CompletedThis completed study tested a same-day approach to hepatitis C testing and treatment in community organizations in Bangkok, Thailand. It involved 200 adults who tested positive for hepatitis C antibodies. The goal was to see if offering immediate treatment with direct-acting anti…
Phase: NA • Sponsor: Institute of HIV Research and Innovation Foundation, Thailand • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
Fatty liver drug showdown: ornithine aspartate vs silymarin
Disease control CompletedThis study tested whether ornithine aspartate granules work better than silymarin capsules for non-alcoholic fatty liver disease (NAFLD). 237 adults with NAFLD and elevated liver enzymes took one of the two treatments for a period. The main goal was to see if liver fat levels imp…
Phase: PHASE4 • Sponsor: Xinhua Hospital, Shanghai Jiao Tong University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
Experimental combo for bile duct cancer shows promise in tiny trial
Disease control CompletedThis phase 2 study tested a combination of two drugs, durvalumab and SNDX-6352, in 5 people with advanced bile duct cancer that had not spread beyond the liver. Participants first received standard chemo or radiation therapy directly into the liver, then the drug combination. The…
Phase: PHASE2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
High-dose radiation beams target liver tumors with precision
Disease control CompletedThis study tested a high-precision radiation treatment called stereotaxic radiotherapy (CyberKnife) in 44 adults with a single liver cancer tumor. The goal was to stop the tumor from growing for at least 18 months. Participants received three high-dose radiation sessions over 8-1…
Phase: PHASE2 • Sponsor: Centre Oscar Lambret • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
New drug combo targets liver damage and alcohol use in one shot
Disease control CompletedThis study tested whether certain drugs (NNC0194-0499, semaglutide, and cagrilintide) can reduce liver damage and alcohol use in people with alcohol-related liver disease. About 270 adults with a history of heavy drinking took part. Participants received different drug combinatio…
Phase: PHASE2 • Sponsor: Novo Nordisk A/S • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New drug cocktail shows promise for tough bile duct cancer
Disease control CompletedThis study tested a combination of the targeted drug regorafenib with chemotherapy (mGEMOX) in 66 people with advanced bile duct cancer that could not be removed by surgery. The main goal was to find the safest dose and check for side effects. This is not a cure, but aims to cont…
Phase: PHASE1, PHASE2 • Sponsor: Institut du Cancer de Montpellier - Val d'Aurelle • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Immunotherapy drug shows limited promise in tough bile duct cancer
Disease control CompletedThis phase 2 trial tested the immunotherapy drug nivolumab (Opdivo) in 54 patients with advanced biliary tract cancer that had stopped responding to chemotherapy. The goal was to see if the drug could shrink tumors. While nivolumab is approved for other cancers, it is not yet app…
Phase: PHASE2 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New Lab-Grown albumin could ease fluid swelling in liver patients
Disease control CompletedThis early-phase trial tested a lab-made version of human serum albumin (r-HSA) in 36 people with cirrhosis and ascites (fluid buildup in the belly). The goal was to check safety, how the body processes the drug, and whether it might help. Participants received one of three doses…
Phase: PHASE1 • Sponsor: Protgen Ltd • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Experimental drug aims to tame rare liver disease
Disease control CompletedThis study tested a new drug called CNP-104 in 42 adults with primary biliary cholangitis, a rare liver disease, who did not get better with standard treatments. The drug is designed to calm the immune system's attack on the bile ducts. The main goals were to check safety and see…
Phase: PHASE1, PHASE2 • Sponsor: COUR Pharmaceutical Development Company, Inc. • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Lab-Made albumin could replace donor protein for liver patients
Disease control CompletedThis study tested whether a lab-made version of a blood protein (recombinant human serum albumin) works as well as the natural version for treating fluid buildup in the belly (ascites) caused by severe liver disease. 390 adults with liver cirrhosis and ascites took part. The goal…
Phase: PHASE2, PHASE3 • Sponsor: Protgen Ltd • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Can two old drugs together save young livers?
Disease control CompletedThis study tested whether giving both midodrine (a blood-pressure drug) and albumin (a protein infusion) to children with cirrhosis and fluid buildup (ascites) could prevent serious complications like kidney injury, low sodium, and confusion. Sixty-one children were split into tw…
Phase: NA • Sponsor: Institute of Liver and Biliary Sciences, India • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Which drug wins? trial pits terlipressin against octreotide for kidney crisis
Disease control CompletedThis study compares two medicines, terlipressin and octreotide, for treating hepatorenal syndrome—a serious kidney complication of advanced liver disease. Sixty adults aged 30 to 70 will receive one of the drugs, and doctors will check kidney function after 48 hours to see which …
Phase: NA • Sponsor: Lahore General Hospital • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New hope for liver cancer: triple therapy shows promise
Disease control CompletedThis study tests whether adding a third drug, ipilimumab, to the standard two-drug combination (atezolizumab and bevacizumab) improves survival and tumor shrinkage in people with advanced liver cancer. About 229 patients will receive either the standard two drugs or all three. Th…
Phase: PHASE2, PHASE3 • Sponsor: Federation Francophone de Cancerologie Digestive • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New bispecific antibody shows promise for unresectable liver cancer
Disease control CompletedThis phase II trial tested a drug called AK112 in 40 people with advanced liver cancer that could not be removed by surgery. AK112 is a bispecific antibody that targets two proteins (PD-1 and VEGF) involved in cancer growth. The study measured safety and how well the drug shrank …
Phase: PHASE2 • Sponsor: Akeso • Aim: Disease control
Last updated Jun 27, 2026 09:11 UTC
-
New surgical patch aims to stop bleeding faster in liver operations
Disease control CompletedThis study tested a new patch called GATT-Patch to see if it stops bleeding during open liver surgery better than the current patch, TachoSil. 132 adults having planned liver surgery took part. The main goal was to see if bleeding stopped within 3 minutes and did not restart.
Phase: NA • Sponsor: GATT Technologies BV • Aim: Disease control
Last updated Jun 27, 2026 09:11 UTC
-
Artificial liver device tested in humans for first time
Disease control CompletedThis early-stage trial tested a device called miroliverELAP, which uses a bioengineered liver graft to filter blood outside the body, in 10 adults with acute liver failure. The goal was to check safety and see if it can support the liver for up to 48 hours, giving time for recove…
Phase: PHASE1 • Sponsor: Miromatrix Medical Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
New drug cocktail shows promise against tough cancers
Disease control CompletedThis study tested a combination of two experimental drugs, AK112 and AK117, with or without chemotherapy, in 154 people with advanced solid tumors. The goal was to see if the combo could shrink tumors and control the disease. The trial has finished, and researchers are now lookin…
Phase: PHASE1, PHASE2 • Sponsor: Akeso • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
Targeted drug shows promise for rare bile duct cancer
Disease control CompletedThis study tested an experimental drug called E7090 in 63 people with advanced bile duct cancer that has a specific genetic change (FGFR2 fusion). Participants had already tried chemotherapy without success. The goal was to see if the drug could shrink tumors. Results help determ…
Phase: PHASE2 • Sponsor: Eisai Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
New targeted pill shows promise for Hard-to-Treat bile duct cancers
Disease control CompletedThis study tested a new oral drug called RLY-4008 in 490 adults with advanced bile duct cancer or other solid tumors that have specific FGFR2 gene changes. The drug is designed to block the FGFR2 protein, which can drive cancer growth. The trial aimed to find the safest dose and …
Phase: PHASE1, PHASE2 • Sponsor: Elevar Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
Computer-Guided drug dosing shows promise for diabetic patients with liver disease
Disease control CompletedThis study tested whether using a computer model to adjust doses of two common drugs (sitagliptin for diabetes and duloxetine for nerve pain) works better in people with liver cirrhosis. 64 patients with cirrhosis, diabetes, and nerve pain were grouped by liver severity and given…
Phase: PHASE4 • Sponsor: Kafrelsheikh University • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
New combo therapy shows promise for tough-to-treat liver cancer
Disease control CompletedThis study tested a combination of an immunotherapy drug (durvalumab) and chemotherapy delivered directly to the liver (HAIC) in 30 adults with advanced liver cancer that had spread into the main portal vein. The goal was to see if the combination could improve one-year survival.…
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
Keyhole vs. open surgery: which is safer for pancreatic cancer?
Disease control CompletedThis study compared two surgical methods—laparoscopic (keyhole) and open surgery—for treating a rare cancer near the pancreas called periampullary adenocarcinoma. Forty patients were enrolled to see which approach led to fewer complications like pancreatic fistula. The goal was t…
Phase: NA • Sponsor: Theodor Bilharz Research Institute • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
Placenta extract shows promise for liver disease in early trial
Disease control CompletedThis completed Phase 2 trial tested LAENNEC, a substance made from human placenta, in 49 adults with chronic liver disease. The study aimed to check if the treatment is safe and whether it can improve liver function, measured by a drop in ALT levels. Participants received either …
Phase: PHASE2 • Sponsor: Green Cross Wellbeing • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
New drug targets rare gene mutations in advanced cancers
Disease control CompletedThis phase II trial tested the drug infigratinib in 17 adults with advanced or metastatic solid tumors that have specific FGFR gene mutations. The drug works by blocking overactive FGFR proteins that help cancer grow. The study measured how many patients' tumors shrank or stabili…
Phase: PHASE2 • Sponsor: Sameek Roychowdhury • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
Could probiotics help tame fatty liver?
Disease control CompletedThis study tested three different probiotics (Pediococcus pentosaceus, Lactobacillus lactis, and Lactobacillus helveticus) in 89 adults with non-alcoholic fatty liver disease. Participants took probiotic capsules or a placebo daily for 8 weeks, along with a standard liver supplem…
Phase: PHASE1, PHASE2 • Sponsor: Chuncheon Sacred Heart Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
New app aims to empower liver cirrhosis patients
Disease control CompletedThis study tested a smartphone app called ReLiver-N designed to help people with liver cirrhosis take a more active role in their care. The app provides health education, self-management tools, and a system to flag urgent issues. Researchers enrolled 48 patients with mild to mode…
Phase: NA • Sponsor: Akdeniz University • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
New pill targets genetic flaw in tough cancers
Disease control CompletedThis early-phase trial tested an oral drug called AG-120 in 174 people with advanced solid tumors (including bile duct cancer, cartilage cancer, and brain tumors) that have a specific IDH1 mutation. The study first found a safe dose, then expanded to see how well the drug works. …
Phase: PHASE1 • Sponsor: Institut de Recherches Internationales Servier • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
New combo therapy shows promise for Hard-to-Treat cancers
Disease control CompletedThis study tested two or three drugs together in adults with advanced solid tumors (cancers that have spread). The main goal was to find the safest dose and see if the combination can shrink tumors. Participants took brigimadlin pills and received ezabenlimab infusions every 3 we…
Phase: PHASE1 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
Can a tropical fruit rind help Pre-Diabetic obesity? new study investigates
Disease control CompletedThis study tested whether Garcinia cambogia rind powder, a dietary supplement, can improve weight, blood sugar, and cholesterol in 90 pre-diabetic obese adults aged 30-60. Participants took the powder daily for 12 weeks. The goal was to see if it helps control metabolic problems …
Phase: NA • Sponsor: University of Lahore • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
New drug combo shows promise for tough liver cancer
Disease control CompletedThis study tested a combination of two drugs, SHR-1210 (an immunotherapy) and apatinib (a targeted therapy), in 190 adults with advanced liver cancer that did not respond to or could not tolerate prior treatment. The goal was to see if the combination could shrink tumors and cont…
Phase: PHASE2 • Sponsor: Jiangsu HengRui Medicine Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
New combo aims to stop liver cancer recurrence in High-Risk patients
Disease control CompletedThis early-stage trial tested whether combining donafinib (a targeted therapy) with an anti-PD-1 antibody (an immunotherapy) can safely prevent liver cancer from coming back after surgery. It involved 30 patients with high-risk features like microvascular invasion or multiple tum…
Phase: PHASE1 • Sponsor: Zhejiang University • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
New hope for autoimmune hepatitis patients who fail standard treatment
Disease control CompletedThis study tested a new biologic drug called VAY736 in 68 adults with autoimmune hepatitis who did not get better with or could not tolerate standard treatments. The goal was to see if VAY736 could safely help normalize liver enzyme levels. Participants received either VAY736 or …
Phase: PHASE2, PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
New hope for bleeding risk in hepatitis b patients?
Disease control CompletedThis study tested the drug eltrombopag in 48 Chinese adults with chronic hepatitis B and a bleeding disorder called immune thrombocytopenia (low platelets). The goal was to see if taking eltrombopag for 6 to 22 weeks could safely raise platelet counts. The trial is complete, but …
Phase: PHASE2 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
New combo shows promise for tough bile duct cancer
Disease control CompletedThis study tested a combination of an immunotherapy drug (nivolumab) and chemotherapy drugs (nanoliposomal-irinotecan, 5-fluorouracil, and leucovorin) in 34 people with advanced biliary tract cancer that had worsened after initial treatment. The goal was to see if the combo could…
Phase: PHASE1, PHASE2 • Sponsor: University of Michigan Rogel Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
New technique shields healthy liver during cancer radiation
Disease control CompletedThis study tested a method to protect healthy liver tissue during Yttrium-90 radioembolization, a radiation treatment for liver cancer. Doctors injected short-acting gelatin particles into arteries supplying non-cancerous liver areas to temporarily block blood flow. The goal was …
Phase: NA • Sponsor: Next Biomedical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
New patch aims to stop bleeding faster in keyhole surgery
Disease control CompletedThis trial tested a new device called GATT-Patch, a flexible, resorbable patch that helps stop bleeding during minimally invasive (keyhole) liver and gallbladder surgeries. 53 adults were randomly assigned to receive either GATT-Patch or a standard surgical patch. The main goal w…
Phase: NA • Sponsor: GATT Technologies BV • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
Team approach boosts weight loss in fatty liver disease
Disease control CompletedThis study tested a team-based approach for people with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), a type of fatty liver linked to heart problems. 286 adults received either standard care or extra support from a liver doctor, a nutritionist, and a psycholog…
Phase: NA • Sponsor: University of Campania Luigi Vanvitelli • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
New hope for hepatitis b: experimental combo aims to silence the virus
Disease control CompletedThis early-stage trial tested two experimental drugs, tobevibart and elebsiran, alone or with standard treatments, in 33 adults with chronic hepatitis B. The goal was to see if these combinations could safely suppress the virus and reduce hepatitis B surface antigen levels. The s…
Phase: PHASE1, PHASE2 • Sponsor: Vir Biotechnology, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
Can a statin boost liver cancer survival?
Disease control CompletedThis study tested whether adding the cholesterol-lowering drug pravastatin to the standard cancer drug sorafenib helps people with advanced liver cancer live longer. It included 474 adults with Child-Pugh A cirrhosis whose cancer could not be cured. The main goal was to see if th…
Phase: PHASE3 • Sponsor: Centre Hospitalier Universitaire Dijon • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
New liver cancer treatment shows promise in early trial
Disease control CompletedThis early-stage study tested a chemotherapy drug called idarubicin mixed with a contrast oil (lipiodol) injected directly into the liver artery for people with liver cancer that cannot be removed by surgery. The 15 participants all had cirrhosis. The goal was to find a safe dose…
Phase: PHASE1 • Sponsor: Centre Hospitalier Universitaire Dijon • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
Artificial intelligence spots hidden liver scarring from simple blood tests
Diagnosis CompletedThis study tests a computer program called NIMIT-AI that analyzes routine blood test results over multiple doctor visits to detect liver scarring in people with fatty liver disease (MASLD). Unlike the current standard method (FIB-4), which often misses cases and fails with incomp…
Sponsor: Siriraj Hospital • Aim: Diagnosis
Last updated Jul 02, 2026 00:00 UTC
-
New device could diagnose fatty liver without needles
Diagnosis CompletedThis study tests whether a device called Fibroscan can diagnose fatty liver disease (steatosis) without needing a biopsy. Researchers will measure liver stiffness and viscosity in 72 people, including healthy volunteers and patients with confirmed fatty liver. Results will be com…
Phase: NA • Sponsor: University Hospital, Tours • Aim: Diagnosis
Last updated Jun 27, 2026 14:00 UTC
-
Could a simple breath test spot hidden diseases early?
Diagnosis CompletedThis study is testing a portable, non-invasive breath analyzer that measures tiny particles in exhaled breath to screen for conditions like type 2 diabetes, liver disease, kidney disease, and lung disease. Researchers will enroll healthy volunteers and people with known diagnoses…
Sponsor: Respyr • Aim: Diagnosis
Last updated Jun 27, 2026 13:07 UTC
-
New blood test may spot liver cancer sooner in High-Risk patients
Diagnosis CompletedThis study looked at 639 adults with cirrhosis to see if a blood test called mSEPT9 can detect liver cancer (hepatocellular carcinoma) better than the current standard test (AFP). Participants gave an extra blood sample during routine care, and researchers compared how well each …
Phase: NA • Sponsor: Central Hospital, Nancy, France • Aim: Diagnosis
Last updated Jun 27, 2026 13:07 UTC
-
New biopsy technique may spot hidden abdominal cancers without major surgery
Diagnosis CompletedThis study looked at how well a special biopsy method called EUS-FNB can diagnose hard-to-reach tumors in the abdomen, such as those near the bile duct or small intestine. Researchers reviewed data from 131 patients who had this procedure over 10 years. The goal was to see if thi…
Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS • Aim: Diagnosis
Last updated Jun 27, 2026 13:01 UTC
-
Could a $10 ruler save newborns from brain damage?
Diagnosis CompletedThis study tested a simple, low-cost plastic ruler called the Bili-ruler to screen newborns for jaundice. Over 4,000 infants were checked with the ruler, a standard device, and visual inspection. The goal was to see if the ruler can accurately identify dangerous jaundice, especia…
Sponsor: George Washington University • Aim: Diagnosis
Last updated Jun 27, 2026 12:39 UTC
-
AI and PET scans join forces to grade cancer without a biopsy
Diagnosis CompletedThis completed study tested whether combining PET/MRI scans with machine learning could better assess how aggressive prostate cancer and other solid tumors are. Researchers enrolled 50 adults with prostate cancer, liver cancer, brain tumors, or kidney cancer. The goal was to see …
Sponsor: Ciprian Catana, MD, PhD • Aim: Diagnosis
Last updated Jun 27, 2026 12:37 UTC
-
Which biopsy method best spots bile duct cancer?
Diagnosis CompletedThis study looked at different ways to take tissue samples from the bile duct during a procedure called ERCP. The goal was to see which method is most accurate for finding cancer. 327 adults with unclear bile duct narrowing took part. Researchers compared several biopsy technique…
Sponsor: Mayo Clinic • Aim: Diagnosis
Last updated Jun 27, 2026 12:36 UTC
-
New ultrasound trick spots liver cancer treatment success days earlier
Diagnosis CompletedThis study tested a new ultrasound technique (Side-by-Side Contrast-Enhanced Ultrasound) to see if it could accurately check whether microwave ablation fully destroyed liver tumors just 1-3 days after treatment. Researchers compared it to standard contrast-enhanced ultrasound in …
Phase: NA • Sponsor: The First Hospital of Jilin University • Aim: Diagnosis
Last updated Jun 27, 2026 12:35 UTC
-
AI takes on radiologists: can a computer beat the standard for liver cancer diagnosis?
Diagnosis CompletedThis study tested a new artificial intelligence (AI) algorithm against the standard LI-RADS criteria for diagnosing liver cancer (hepatocellular carcinoma) on CT scans. Researchers enrolled 300 people at risk for liver cancer who had a new liver nodule found on ultrasound. The go…
Phase: NA • Sponsor: The University of Hong Kong • Aim: Diagnosis
Last updated Jun 27, 2026 12:33 UTC
-
Blood test may spare unneeded liver biopsies for fatty liver patients
Diagnosis CompletedThis study looked at whether giving doctors the results of a blood test called ELF helps them better diagnose advanced liver scarring (fibrosis) in people with fatty liver disease. About 450 patients were randomly assigned to have the ELF test or not during their liver clinic vis…
Phase: NA • Sponsor: University of Kansas Medical Center • Aim: Diagnosis
Last updated Jun 27, 2026 12:32 UTC
-
Quick strip test could speed up infection diagnosis in cirrhosis patients
Diagnosis CompletedThis study tested a simple strip test called PeriScreen to quickly diagnose infection in the belly fluid of people with cirrhosis. The goal is to see if the strip can spot infections as accurately as standard lab tests, helping doctors start treatment faster. About 649 adults wit…
Phase: NA • Sponsor: Centre Hospitalier Departemental Vendee • Aim: Diagnosis
Last updated Jun 27, 2026 12:29 UTC
-
New hepatitis b blood tests put to the test on 21,000 samples
Diagnosis CompletedThis study checked how well new blood tests (Access HBV assays) can detect hepatitis B infection. Researchers tested over 21,000 leftover blood samples from adults, including blood donors and hospital patients. The goal was to see if these tests are accurate compared to existing …
Sponsor: Beckman Coulter, Inc. • Aim: Diagnosis
Last updated Jun 27, 2026 12:28 UTC
-
New blood markers could revolutionize liver cancer diagnosis
Diagnosis CompletedThis study looked at blood samples from 573 people to find new markers that could diagnose liver cancer more accurately. Researchers compared samples from patients with liver cancer, those with other liver conditions, and people with hepatitis infections. The goal is to improve u…
Sponsor: Stanford University • Aim: Diagnosis
Last updated Jun 27, 2026 12:08 UTC
-
Blow into this tube: a simple breath test might spot liver disease early
Diagnosis CompletedThis study looked at whether a breath test could help detect liver fibrosis, cirrhosis, or liver cancer. Researchers collected breath samples from 56 patients with known or suspected liver disease and analyzed them for specific chemical markers. The goal was to see if the test co…
Sponsor: Imperial College London • Aim: Diagnosis
Last updated Jun 27, 2026 12:02 UTC
-
AI-Powered liver test could spot hidden risks in fatty liver patients
Diagnosis CompletedThis study looked at over 1,200 adults with metabolic fatty liver disease (MASLD) to see if a new digital test, called FibroNest Ph-FCS, can predict who will develop serious liver complications. The test uses computer analysis of standard liver biopsy images to measure scarring. …
Sponsor: PharmaNest, Inc • Aim: Diagnosis
Last updated Jun 27, 2026 12:00 UTC
-
No-Needle liver test: MRI may replace painful biopsies
Diagnosis CompletedThis study tested a new, fully automated MRI technique to diagnose liver fibrosis and inflammation without needing a needle biopsy or contrast dye. Researchers scanned 200 adults with chronic liver disease and compared the MRI results to standard biopsy findings. The goal is to p…
Sponsor: Chinese University of Hong Kong • Aim: Diagnosis
Last updated Jun 27, 2026 11:02 UTC
-
New blood test could spot hidden liver cancer early
Diagnosis CompletedThis completed study tested a new blood test that looks for tiny particles called exosomal microRNAs to detect intrahepatic cholangiocarcinoma, a rare and aggressive liver cancer. Researchers analyzed blood samples from 535 adults to see how accurately the test could identify can…
Sponsor: City of Hope Medical Center • Aim: Diagnosis
Last updated Jun 27, 2026 11:01 UTC
-
New blood test could spare bile duct cancer patients unnecessary surgery
Diagnosis CompletedThis study tested a new blood test called LyMIC that looks for tiny particles (exosomes) released by cancer cells. The goal was to see if it could accurately tell whether bile duct cancer has spread to nearby lymph nodes before surgery. Researchers analyzed blood samples from 230…
Sponsor: City of Hope Medical Center • Aim: Diagnosis
Last updated Jun 27, 2026 11:00 UTC
-
Quick MRI may outshine ultrasound for liver cancer detection
Diagnosis CompletedThis study tested whether a shorter, contrast-enhanced MRI (called AMRI) is better than standard ultrasound for finding liver cancer early in people with cirrhosis. 79 adults with cirrhosis underwent both scans, and researchers compared how accurately each method detected cancer.…
Phase: PHASE4 • Sponsor: University of California, San Diego • Aim: Diagnosis
Last updated Jun 27, 2026 09:04 UTC
-
New blood test may spot liver cancer earlier in hepatitis c patients
Diagnosis CompletedThis study looked at whether measuring tiny molecules called microRNAs in the blood can help diagnose liver cancer (hepatocellular carcinoma) in people with hepatitis C. Researchers tested blood samples from 84 participants, including healthy people and those with hepatitis C, wi…
Sponsor: Benha University • Aim: Diagnosis
Last updated Jun 27, 2026 09:04 UTC
-
App and peer support aim to boost HIV prevention for people leaving jail
Prevention CompletedThis study tested whether a mobile app (GeoPassport), financial incentives, and peer mentor support could help men who have sex with men and transgender women leaving jail access HIV prevention services like PrEP and testing. 233 participants were enrolled and followed for 9 mont…
Phase: NA • Sponsor: University of California, Los Angeles • Aim: Prevention
Last updated Jun 27, 2026 12:35 UTC
-
Liver patients get brain protection: antibiotic may stop confusion after TIPS
Prevention CompletedThis study tested whether the antibiotic rifaximin could prevent a serious brain condition called hepatic encephalopathy in people with cirrhosis who undergo a TIPS procedure. The TIPS procedure helps reduce pressure in the liver but often leads to confusion and other brain issue…
Phase: PHASE3 • Sponsor: University Hospital, Toulouse • Aim: Prevention
Last updated Jun 27, 2026 12:29 UTC
-
Cheap antibiotic may prevent deadly infection in liver patients
Prevention CompletedThis study looked at whether doxycycline, a common antibiotic, can prevent spontaneous bacterial peritonitis (SBP) in people with cirrhosis. SBP is a serious infection of the belly fluid that can be life-threatening. The study included 841 adults with cirrhosis who were at risk f…
Sponsor: Methodist Health System • Aim: Prevention
Last updated Jun 27, 2026 11:03 UTC
-
Simple combo could stop hepatitis b passed from mom to baby
Prevention CompletedThis study tested whether giving pregnant women with hepatitis B a daily pill (tenofovir) plus giving their newborns a hepatitis B vaccine at birth could safely prevent the virus from passing to the baby. The trial enrolled 317 women in the Democratic Republic of Congo and follow…
Phase: PHASE4 • Sponsor: University of North Carolina, Chapel Hill • Aim: Prevention
Last updated Jun 27, 2026 09:06 UTC
-
Simple home workouts may boost strength before liver transplant
Symptom relief CompletedThis study tested whether a personalized home exercise program (walking three times a week and strength training with elastic bands twice a week) could improve fitness and strength in 30 adults waiting for a liver transplant. The goal was to see if better fitness before surgery c…
Phase: NA • Sponsor: University Hospital, Limoges • Aim: Symptom relief
Last updated Jun 27, 2026 14:03 UTC
-
New pain block could cut opioid use after liver transplant
Symptom relief CompletedThis study tested whether a nerve block called the external oblique intercostal plane block can reduce pain after liver transplant surgery. Sixty-four adult patients received either the block or a sham procedure after surgery. Researchers measured how much morphine patients neede…
Phase: NA • Sponsor: Istinye University • Aim: Symptom relief
Last updated Jun 27, 2026 14:02 UTC
-
New drug aims to let sunlight-sensitive patients enjoy the sun longer
Symptom relief CompletedThis study tested a drug called MT-7117 in 165 adults and adolescents (ages 12-75) with erythropoietic protoporphyria (EPP) or X-linked protoporphyria (XLP), conditions that cause severe pain from sunlight exposure. The goal was to see if the drug could delay the first symptoms o…
Phase: PHASE3 • Sponsor: Tanabe Pharma America, Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 13:02 UTC
-
Lidocaine spray may reduce muscle relaxant needed for tube insertion
Symptom relief CompletedThis study tested whether using a lidocaine spray along with a low dose of a muscle relaxant (cisatracurium) can make placing a breathing tube easier and safer during ERCP, a procedure for bile duct problems. 186 adults with liver issues were randomly assigned to receive either t…
Phase: PHASE4 • Sponsor: Jiangang Song • Aim: Symptom relief
Last updated Jun 27, 2026 12:38 UTC
-
String-Attached stent may ease bile duct cancer surgery prep
Symptom relief CompletedThis pilot study tested a plastic stent with a retrieval string to drain bile in 40 people with resectable bile duct cancer. The goal was to see if the stent could safely reduce bile buildup before surgery. Researchers measured serious complications and how well the stent worked.
Phase: NA • Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) • Aim: Symptom relief
Last updated Jun 27, 2026 12:37 UTC
-
Walking program shows promise for liver patients
Symptom relief CompletedThis study looked at whether a 16-week brisk walking program, combined with dietary advice, could improve heart rate control and blood vessel health in adults with early-stage cirrhosis (liver scarring). Fifty participants aged 45-75 who were not very active took part. The goal w…
Phase: NA • Sponsor: King Chulalongkorn Memorial Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 12:36 UTC
-
Can a home exercise program help liver transplant patients get stronger?
Symptom relief CompletedThis study tested a home-based physical therapy program called LIFT for people with liver cirrhosis waiting for a transplant. The program included a personalized exercise plan, a smartphone app to track progress, daily text reminders, and regular phone check-ins. The goal was to …
Phase: NA • Sponsor: Northwestern University • Aim: Symptom relief
Last updated Jun 27, 2026 12:33 UTC
-
Can breathing and meditation ease PBC symptoms? new study says maybe.
Symptom relief CompletedThis study tested a 10-week online wellness program for women with primary biliary cholangitis (PBC), a chronic liver disease that causes fatigue, itching, brain fog, and emotional distress. The program included guided breathing, meditation, gentle movement, and optional nutritio…
Phase: NA • Sponsor: University of Alberta • Aim: Symptom relief
Last updated Jun 27, 2026 12:31 UTC
-
Can an online wellness program ease anxiety in chronic disease?
Symptom relief CompletedThis study tested a 12-week online mind-body program for adults with chronic conditions like heart failure, cancer, and liver disease. The program included mindful movement, meditation, breathwork, and coping skills. Researchers measured changes in anxiety, depression, fatigue, a…
Phase: NA • Sponsor: University of Alberta • Aim: Symptom relief
Last updated Jun 27, 2026 12:31 UTC
-
Teleyoga tested for liver transplant recovery
Symptom relief CompletedThis study looked at whether doing yoga online for 8 weeks could improve balance, frailty, thinking skills, and quality of life in people who had a liver transplant. Eleven patients took part. The goal was to see if a convenient home-based program could help them feel better and …
Phase: NA • Sponsor: Dokuz Eylul University • Aim: Symptom relief
Last updated Jun 27, 2026 12:30 UTC
-
New program aims to bridge racial gaps in end-of-life care
Symptom relief CompletedThis study tested a program called PRISM, which teaches skills like stress management and goal setting, to see if it helps racial minority patients with serious illnesses feel more resilient and communicate better with their healthcare providers. The study enrolled 28 seriously i…
Phase: PHASE1, PHASE2 • Sponsor: University of Washington • Aim: Symptom relief
Last updated Jun 27, 2026 12:26 UTC
-
Can old drugs ease bladder and asthma symptoms in liver disease?
Symptom relief CompletedThis study looked at whether two drugs, mirabegron and montelukast, are safe and helpful for people with liver cirrhosis who also have overactive bladder and asthma. 78 participants took part over 3 months. Researchers tracked bladder symptoms, breathing issues, and side effects …
Phase: PHASE4 • Sponsor: Kafrelsheikh University • Aim: Symptom relief
Last updated Jun 27, 2026 12:07 UTC
-
Could a gentle electric zap at key points make emergency gut exams easier for liver patients?
Symptom relief CompletedThis study tested whether a mild electrical stimulation at specific acupoints (TEAS) helps people with cirrhosis tolerate an urgent endoscopy for suspected variceal bleeding. 180 patients were split into three groups: active TEAS, sham TEAS (electrodes but no current), or standar…
Phase: NA • Sponsor: Beijing 302 Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 12:06 UTC
-
Simple cover and massage may speed up jaundice treatment in newborns
Symptom relief CompletedThis study looked at whether placing a white cover over the incubator and giving gentle massage during phototherapy can lower bilirubin levels faster in newborns with jaundice caused by ABO incompatibility. Sixty full-term babies were included. The goal was to see if these simple…
Phase: NA • Sponsor: Karabuk University • Aim: Symptom relief
Last updated Jun 27, 2026 12:05 UTC
-
Mindfulness may ease stress for liver patients
Symptom relief CompletedThis study looked at whether mindfulness exercises can lower stress and improve communication between patients with liver disease and their doctors. 56 adults took part, answering surveys about their stress, anxiety, and how well they felt they could share decisions with their he…
Sponsor: Methodist Health System • Aim: Symptom relief
Last updated Jun 27, 2026 12:00 UTC
-
New sleep drug shows promise for liver patients
Symptom relief CompletedThis study tested a sleep medication called lemborexant in 82 adults with liver cirrhosis who had trouble sleeping. The drug works by blocking wakefulness signals in the brain. Researchers measured sleep quality and checked for side effects on the liver. The goal was to see if le…
Phase: PHASE2 • Sponsor: Indonesia University • Aim: Symptom relief
Last updated Jun 27, 2026 11:03 UTC
-
New pill could ease carcinoid syndrome Flare-Ups
Symptom relief CompletedThis Phase 2 trial tested paltusotine, an oral drug, in 36 adults with carcinoid syndrome. The study looked at safety and how the body processes the drug at different doses. Participants were randomly assigned to 40 mg or 80 mg daily, with dose adjustments allowed. The goal is to…
Phase: PHASE2 • Sponsor: Crinetics Pharmaceuticals Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 11:02 UTC
-
Can a single pill ease pain after liver cancer procedure?
Symptom relief CompletedThis study tested whether giving a single dose of pregabalin before a liver cancer ablation procedure can reduce pain afterward. 70 adults with liver cancer were randomly assigned to receive either pregabalin or a placebo before their procedure. The main goal was to measure pain …
Phase: PHASE4 • Sponsor: Sherief Abd-Elsalam • Aim: Symptom relief
Last updated Jun 27, 2026 11:01 UTC
-
Kitchen foil vs bed sheet: which boosts jaundice treatment best?
Symptom relief CompletedThis study tested whether adding reflective materials like aluminum foil or white cloth around babies during light therapy for jaundice helps lower bilirubin faster. 81 newborns with mild jaundice were randomly assigned to standard therapy, therapy with white cloth reflectors, or…
Phase: NA • Sponsor: Kubra Nur Kabakcı Sarıdağ • Aim: Symptom relief
Last updated Jun 27, 2026 09:10 UTC
-
PET-CT scans could sharpen radiation targeting for liver tumors
Knowledge-focused CompletedThis study investigates whether PET-CT scans can accurately measure the radiation dose delivered by radioactive spheres during a liver cancer treatment called radioembolization. Researchers will compare scans taken before and after the procedure in patients with liver tumors. The…
Phase: NA • Sponsor: Fox Chase Cancer Center • Aim: Knowledge-focused
Last updated Jul 04, 2026 00:00 UTC
-
Decade-Long study aims to unlock liver disease risks in HIV-Hepatitis b patients
Knowledge-focused CompletedThis study follows adults in Zambia who have both HIV and chronic hepatitis B to track liver health over up to 10 years. Researchers aim to understand how current HIV treatments affect hepatitis B and liver damage, and to identify factors that lead to serious outcomes like liver …
Sponsor: University of Alabama at Birmingham • Aim: Knowledge-focused
Last updated Jul 04, 2026 00:00 UTC
-
Small study aims to unlock secrets of rare lung disease
Knowledge-focused CompletedThis completed Phase 1 study looked at 27 people with and without pulmonary hypertension to learn more about how blood vessel problems contribute to the disease. Researchers used heart catheterization, imaging, and blood tests to find biomarkers and understand disease mechanisms.…
Phase: PHASE1 • Sponsor: National Institutes of Health Clinical Center (CC) • Aim: Knowledge-focused
Last updated Jul 04, 2026 00:00 UTC
-
Blood safety watch: 1,771 transfusion patients tracked for hidden infections
Knowledge-focused CompletedThis study followed 1,771 adults and children who received blood transfusions to check how safe the blood supply is. Researchers tested patients' blood for viruses like HIV and hepatitis before and after transfusion, and stored samples for future testing. The goal was to keep blo…
Sponsor: National Institutes of Health Clinical Center (CC) • Aim: Knowledge-focused
Last updated Jul 02, 2026 00:00 UTC
-
Fatty liver mystery: could how we process food be the key?
Knowledge-focused CompletedThis study looked at how people with and without non-alcoholic fatty liver disease (NAFLD) process food. Researchers monitored 53 adults over two days, measuring metabolism, blood, and urine after meals. The goal was to find differences that might explain why fat builds up in the…
Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) • Aim: Knowledge-focused
Last updated Jul 02, 2026 00:00 UTC
-
Can a quick chat with a radiotherapy tech ease cancer patients' anxiety?
Knowledge-focused CompletedThis study looked at whether having a special consultation with a radiotherapy technician (called a manipulator) helps cancer patients feel more informed about their treatment. Researchers enrolled 308 adults with various cancers who were getting radiation therapy. They compared …
Phase: NA • Sponsor: Centre Antoine Lacassagne • Aim: Knowledge-focused
Last updated Jul 02, 2026 00:00 UTC
-
Can genes predict liver damage from childhood cancer drugs?
Knowledge-focused CompletedThis study investigates whether certain genetic differences make children with nephroblastoma (kidney cancer) or acute lymphoblastic leukemia (blood cancer) more likely to develop a serious liver condition called hepatic veno-occlusive disease (VOD) during chemotherapy. Researche…
Phase: NA • Sponsor: University Hospital, Angers • Aim: Knowledge-focused
Last updated Jul 01, 2026 00:00 UTC
-
Liver function may change how tirabrutinib acts in the body
Knowledge-focused CompletedThis completed Phase 1 study looked at how the drug tirabrutinib is processed in people with mild, moderate, or severe liver impairment compared to healthy volunteers. Forty participants took a single oral dose, and researchers measured drug levels and safety. The goal was to und…
Phase: PHASE1 • Sponsor: Ono Pharmaceutical Co., Ltd. • Aim: Knowledge-focused
Last updated Jun 28, 2026 00:00 UTC
-
Blood protein may reveal hidden nerve damage in diabetes and fatty liver
Knowledge-focused CompletedThis observational study investigates whether a substance in the blood called nociceptin is linked to overactive nerves in people who have both type 2 diabetes and metabolic fatty liver disease. Researchers will compare 50 patients with both conditions to 50 healthy volunteers, m…
Sponsor: Second Hospital of Shanxi Medical University • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:03 UTC
-
Could adding a second diabetes drug early save lives?
Knowledge-focused CompletedThis study analyzed health records of over 118,000 adults with obesity, type 2 diabetes, and related heart, kidney, and liver conditions. Researchers compared people who added a second type of diabetes drug (GLP-1 or SGLT2) early to those who did not. The goal was to see if early…
Sponsor: Chung Shan Medical University • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
Does anesthesia choice impact liver cancer recurrence?
Knowledge-focused CompletedThis study looked at 153 people having liver cancer surgery to see if the type of anesthesia they received affected their recovery and immune response. Researchers compared different anesthesia methods and measured blood markers related to inflammation and immune cell activity. P…
Phase: NA • Sponsor: Iuliu Hatieganu University of Medicine and Pharmacy • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
Lab study tests antibody that could unlock immune attack on liver cancer
Knowledge-focused CompletedThis completed study looked at a new antibody called anti-SIRPα as a potential immunotherapy for liver cancer. Researchers used blood and tissue samples from 30 liver cancer patients to see how the antibody affects immune cells. The goal was to understand whether blocking the SIR…
Sponsor: Nantes University Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
Study aims to cut hospital time after liver surgery by looking beyond medicine
Knowledge-focused CompletedThis completed study looked at 3000 patients having liver surgery to see if considering both medical and social factors could reduce how long they stay in the hospital. Researchers tracked things like complications and readmissions. The goal is to find ways to improve recovery an…
Sponsor: Centre Hospitalier Universitaire, Amiens • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
Blood donors help unlock secrets of hepatitis c
Knowledge-focused CompletedThis study looked at 805 blood donors who tested positive for hepatitis C virus (HCV) to learn how the virus spreads and affects health over time. Researchers collected blood samples and health information to track infection and liver disease. The goal was to better understand HC…
Sponsor: National Institutes of Health Clinical Center (CC) • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:01 UTC
-
Swallowable capsule could unlock secrets of Gut-Liver connection
Knowledge-focused CompletedThis study tests whether a special capsule, called SIMBA, can safely collect fluid from the small intestine in people with liver cirrhosis. Participants swallow two capsules, which are later recovered from stool. Researchers will analyze the fluid to compare gut bacteria and meta…
Phase: NA • Sponsor: Vanessa Stadlbauer-Koellner, MD • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:01 UTC
-
Hepatitis b drug holiday: study tests if stopping pills is safe
Knowledge-focused CompletedThis study tested whether people with chronic hepatitis B who had been on antiviral drugs for at least 4 years could safely stop treatment. Fifteen adults were monitored with monthly blood tests for 6 months after stopping, then every 3 months. The goal was to see if the virus st…
Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
HIV drug side effects: new study probes liver damage risk
Knowledge-focused CompletedThis study looked at liver fibrosis (scarring) in 127 HIV patients who had high liver enzymes while on antiretroviral therapy. Participants underwent tests like liver biopsy, ultrasound, and CT scans to measure liver damage. The goal was to understand how common and severe liver …
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Hepatitis c study tests whether a patient registry is possible in vietnam
Knowledge-focused CompletedThis study looked at whether it's possible to create a group of people with hepatitis C in Hai Phong, Vietnam, for future research. 300 adults with active hepatitis C took part. The goal was to see how many patients could be enrolled and how much information could be collected, n…
Sponsor: Centre Hospitalier Universitaire de Nīmes • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Liver study tests new drug dosing
Knowledge-focused CompletedThis study looked at how the body processes a single dose of the drug etavopivat in people with mild, moderate, or severe liver disease compared to those with healthy livers. 48 adults took part. The goal was to understand how liver function affects drug levels and safety, which …
Phase: PHASE1 • Sponsor: Novo Nordisk A/S • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Hidden hepatitis e threat in transplant patients?
Knowledge-focused CompletedThis study checked how many organ transplant recipients in the U.S. have antibodies to the hepatitis E virus, which can become chronic in people with weakened immune systems. Researchers enrolled 447 adults who had a liver, kidney, or small bowel transplant or were on a waiting l…
Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Liver study checks drug safety in 24 volunteers
Knowledge-focused CompletedThis study looked at how the drug ITF2357 is handled by the body in people with chronic liver disease compared to healthy volunteers. 24 adults received a single 50 mg dose by mouth. The goal was to measure drug levels and check safety, not to treat the liver condition.
Phase: PHASE1 • Sponsor: Italfarmaco • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Scientists probe Gut-Liver link in alcohol and fatty liver cancers
Knowledge-focused CompletedThis study looked at 180 people with liver cancer (hepatocellular carcinoma) who also had cirrhosis caused by either fatty liver disease or alcohol use. Researchers compared immune cells and gut bacteria in the liver to understand why cancer develops. The goal was to gather knowl…
Sponsor: Centre Hospitalier Universitaire de Nice • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Hidden pain in liver patients: a new study investigates
Knowledge-focused CompletedThis completed study looked at how often hospitalized patients with cirrhosis experience pain. Researchers asked 30 patients about their pain, its location, intensity, and whether it was chronic. The goal was to highlight an often-overlooked issue and encourage better pain care f…
Sponsor: Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Vitamin e study aims to uncover how body fat affects nutrient needs in women
Knowledge-focused CompletedThis completed Phase 1 study looked at how vitamin E is absorbed and used in the bodies of normal-weight and obese women, and whether vitamin C helps. Fifty women aged 18 to 40 took part, including some with type 2 diabetes. Researchers gave different doses of vitamin E (by mouth…
Phase: PHASE1 • Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Hepatitis b mutations linked to higher virus levels
Knowledge-focused CompletedThis study looks at how certain genetic changes (mutations) in the hepatitis B virus (HBV) affect the amount of virus in the blood of people with chronic infection. Researchers analyzed blood samples from 92 patients not on antiviral treatment. They found that specific mutations …
Sponsor: Centre Hospitalier Universitaire, Amiens • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Can shedding pounds heal the liver? new study investigates
Knowledge-focused CompletedThis study looked at 255 people with severe obesity who had weight-loss surgery. Researchers wanted to see if losing weight could improve liver scarring (fibrosis) by measuring certain blood tests before and one year after surgery. The goal was to understand how weight loss affec…
Phase: NA • Sponsor: University Hospital, Rouen • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:07 UTC
-
Iron clues could save lives in liver crisis
Knowledge-focused CompletedThis study looked at 98 adults with cirrhosis who were hospitalized for sudden worsening of their liver condition. Researchers measured different forms of iron in the blood to see how they relate to short-term death risk. The goal was to better understand iron's role in liver fai…
Sponsor: Rennes University Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:07 UTC
-
Zambia study tracks hepatitis b outcomes in hundreds of patients
Knowledge-focused CompletedThis study followed 326 adults in Zambia with chronic hepatitis B for up to 5 years. Researchers tracked how the virus behaves, how many patients need treatment, and how many develop serious liver problems like cirrhosis or liver cancer. The goal was to better understand the dise…
Sponsor: University of Alabama at Birmingham • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:06 UTC
-
Liver failure treatment MARS: does it help avoid transplants?
Knowledge-focused CompletedThis study looked back at the medical records of 27 patients with alcoholic hepatitis or sudden liver failure who received a treatment called MARS (a type of dialysis that cleans the blood). The goal was to see if MARS helped them survive without needing a liver transplant. Resea…
Sponsor: Methodist Health System • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:06 UTC
-
Cirrhosis may worsen trauma outcomes, study suggests
Knowledge-focused CompletedThis completed study looked at over 4.7 million trauma patients in the U.S. to see if those with liver cirrhosis have higher death rates and more infections. Researchers compared patients with and without cirrhosis using hospital records from 2010 to 2018. The goal was to better …
Sponsor: Methodist Health System • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:06 UTC
-
Massive french study reveals gaps in liver cancer screening
Knowledge-focused CompletedThis study looked at health insurance records of over 75,000 people with cirrhosis in France to see if doctors follow guidelines for early liver cancer screening. The goal was to find out how often screening is done correctly and what factors might lead to missed or delayed diagn…
Sponsor: Centre Hospitalier Universitaire, Amiens • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:06 UTC
-
Blood tests could spot hidden liver risk in diabetics
Knowledge-focused CompletedThis completed study observed 40 people with type 2 diabetes to find blood markers that could identify those at risk for a serious liver condition called NASH. Researchers measured liver stiffness and calculated scores like FIB-4 and ELF to see which patients might have liver sca…
Sponsor: Faculty Hospital Kralovske Vinohrady • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:06 UTC
-
New liver pressure test shows promise in small study
Knowledge-focused CompletedThis study looked at a new method to measure pressure in the liver's blood vessels during an endoscopic ultrasound. Researchers tested it in 100 adults with liver disease to see if it is safe and works well. The goal was to gather information, not to treat the disease.
Phase: NA • Sponsor: Methodist Health System • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:06 UTC
-
Should older hepatitis b patients with normal ALT get antivirals? new study explores
Knowledge-focused CompletedThis study followed 250 chronic hepatitis B patients over age 30 who had detectable virus but normal liver enzyme levels (ALT). All had never received antiviral treatment before. Researchers measured how many became virus-negative after 48 weeks of antiviral therapy, and how many…
Sponsor: Tongji Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:05 UTC
-
DNA collection study aims to unlock secrets of rare liver diseases
Knowledge-focused CompletedThis completed study collected blood or saliva samples from 213 people with rare liver diseases to extract and store their DNA. The goal was to create a genetic resource that scientists can use in future studies to explore the causes, biomarkers, and genetic factors of these cond…
Sponsor: Arbor Research Collaborative for Health • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:03 UTC
-
Kids' obesity may change how acid reflux drugs work
Knowledge-focused CompletedThis study looked at how obesity affects the way children's bodies process common acid reflux medications like lansoprazole and pantoprazole. Researchers gave a single dose of these drugs to 76 children aged 6-21, both with and without obesity, and measured how long the drugs sta…
Phase: PHASE4 • Sponsor: Children's Mercy Hospital Kansas City • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:02 UTC
-
Liver function and drug processing: a safety study
Knowledge-focused CompletedThis study looked at how a single dose of MY008211A tablets moves through the body in people with different levels of liver function. 24 adults (some with liver problems, some without) took part. The goal was to understand safety and how the liver affects drug levels, not to trea…
Phase: PHASE1 • Sponsor: Wuhan Createrna Science and Technology Co., Ltd • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:02 UTC
-
Small study tests best way to mix chemo for liver tumors
Knowledge-focused CompletedThis study looked at 10 people with liver cancer (HCC) who were getting a standard treatment called chemoembolization (c-TACE). The goal was to see if mixing the chemotherapy drug doxorubicin with salt water or a contrast dye changes how the drug spreads inside the tumor. Researc…
Phase: PHASE4 • Sponsor: University Hospital, Strasbourg, France • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:02 UTC
-
New study tests faster hepatitis c detection for drug users
Knowledge-focused CompletedThis study looked at two faster ways to test for hepatitis C in people who recently injected drugs and visit needle exchange programs. One method uses a fingerstick test with results in about an hour, and the other uses a dried blood spot sent to a lab. The goal was to see if the…
Phase: NA • Sponsor: Kirby Institute • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:01 UTC
-
New models aim to predict liver disease in HIV patients
Knowledge-focused CompletedThis study looked at 315 HIV-positive adults to build models that predict fatty liver disease and liver scarring. Researchers used ultrasound and FibroScan tests to track liver changes over time. The goal was to better understand and identify liver problems early in people living…
Sponsor: Shanghai Public Health Clinical Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:01 UTC
-
Scientists Fine-Tune ultrasound to spot fatty liver without needles
Knowledge-focused CompletedThis completed study tested different ways to use an ultrasound machine to measure liver fat in 35 healthy adults. The goal was to find the most reliable technique for non-invasively diagnosing fatty liver disease, a common condition linked to obesity and diabetes. By standardizi…
Sponsor: Fondazione IRCCS Policlinico San Matteo di Pavia • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:01 UTC
-
Antibiotics before endoscopy: do they prevent infections in liver patients?
Knowledge-focused CompletedThis study looked at 480 cirrhosis patients who had variceal bleeding and were getting an endoscopy to prevent future bleeding. Half got antibiotics before the procedure, half did not. The goal was to see if antibiotics reduce infections after the procedure. The study is retrospe…
Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:00 UTC
-
Smart scans and DNA tests could revolutionize liver cancer care
Knowledge-focused CompletedThis study looked at whether combining detailed MRI scans with whole genome sequencing can help doctors choose the best treatment for people with liver cancer. Researchers studied 200 adults who were scheduled for liver surgery. The goal was to see if these advanced tests provide…
Sponsor: Perspectum • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:00 UTC
-
New cholesterol drug tested in liver patients
Knowledge-focused CompletedThis completed Phase 1 study looked at how the experimental cholesterol-lowering drug enlicitide is processed in the body of people with mild or moderate liver impairment compared to healthy volunteers. Twenty participants received a single oral dose, and researchers measured dru…
Phase: PHASE1 • Sponsor: Merck Sharp & Dohme LLC • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:00 UTC
-
New approach to CPR talks may help patients and families feel heard
Knowledge-focused CompletedThis study tested a new way for doctors to discuss CPR with older, seriously ill patients and their families. Instead of the usual conversation, doctors followed a step-by-step guide that focused on the patient's values and explained why CPR might not help. The goal was to see if…
Phase: PHASE2, PHASE3 • Sponsor: University of Vermont • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:00 UTC
-
New drug tested in people with liver disease
Knowledge-focused CompletedThis study looked at how the body handles a drug called BI 1584862 in people with different levels of liver function. 43 adults with mild, moderate, or severe liver problems, plus a group with healthy livers, took a single dose of the drug. Researchers measured drug levels in the…
Phase: PHASE1 • Sponsor: Boehringer Ingelheim • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:39 UTC
-
Thousands with fatty liver disease monitored to understand long-term risks
Knowledge-focused CompletedThis completed study followed 1,681 people with steatotic liver disease (fatty liver) in Germany to observe how the condition progresses over time. Researchers measured liver stiffness, inflammation, and tracked whether participants developed heart problems or tumors. The goal wa…
Sponsor: Leberstiftungs-GmbH Deutschland • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:39 UTC
-
Liver function study tests drug processing in 29 volunteers
Knowledge-focused CompletedThis study looked at how the drug LY3502970 enters the bloodstream and leaves the body in people with different levels of liver function. 29 participants, including healthy volunteers and those with mild to severe liver impairment, took a single dose. The goal was to understand d…
Phase: PHASE1 • Sponsor: Eli Lilly and Company • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:37 UTC
-
Liver function may change how MCI-186 acts in the body
Knowledge-focused CompletedThis study looked at how the drug MCI-186 (also called edaravone) behaves in people with mild or moderate liver impairment compared to those with healthy livers. Twenty-two participants received a single dose of the drug. The goal was to see if liver problems affect how the drug …
Phase: PHASE1 • Sponsor: Tanabe Pharma Corporation • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:36 UTC
-
Are cirrhosis patients getting the shots they need? french study finds out
Knowledge-focused CompletedThis study looked at how many people with cirrhosis in French general hospitals were vaccinated against diseases like hepatitis, flu, and COVID-19. Researchers surveyed 742 patients to see if they were up to date on their shots. The goal was to find gaps in vaccination coverage s…
Sponsor: Centre Hospitalier Sud Francilien • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:36 UTC
-
Taste test: asian mediterranean diet for fatty liver
Knowledge-focused CompletedThis study tested whether a version of the Mediterranean diet made with Asian ingredients is acceptable to people with non-alcoholic fatty liver disease (NAFLD). 30 participants in Singapore tasted meals from a 4-week menu and rated them. The goal was to see if people liked the f…
Sponsor: Singapore Institute of Technology • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:36 UTC
-
New study aims to fix lack of diversity in cancer trials
Knowledge-focused CompletedThis completed study looked at ways to increase diversity in cancer clinical trials, focusing on breast, liver, and prostate cancers. Researchers worked with communities, doctors, and scientists in New York City to find better ways to include people of color and underserved group…
Phase: NA • Sponsor: Icahn School of Medicine at Mount Sinai • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:36 UTC
-
Race against the clock: urgent endoscopy may not beat waiting for variceal bleed
Knowledge-focused CompletedThis study looked at 412 people with cirrhosis who had bleeding from veins in the esophagus or stomach. Half got an endoscopy within 6 hours, the other half between 6 and 24 hours. The goal was to see if faster treatment lowered the chance of rebleeding within 42 days. The result…
Phase: NA • Sponsor: Jinling Hospital, China • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:34 UTC
-
Massive study tracks fatty liver disease patients to uncover Real-World treatment patterns
Knowledge-focused CompletedThis study followed over 7,300 people with nonalcoholic fatty liver disease (NAFLD) and its more severe form, NASH, in regular doctor visits. Researchers aimed to understand how the disease progresses and what treatments doctors are using, since no drugs are officially approved f…
Sponsor: Target PharmaSolutions, Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:34 UTC
-
Blood tests and surveys may predict cancer treatment success
Knowledge-focused CompletedThis study followed 159 people with metastatic colorectal, pancreatic, biliary, or esophageal cancers who were starting a new line of therapy. Researchers collected blood samples (tumor markers and liquid biopsies) and patient-reported quality-of-life data to see if these could p…
Sponsor: Massachusetts General Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:34 UTC
-
Thousands tracked in Largest-Ever liver cancer bead therapy registry
Knowledge-focused CompletedThis registry followed over 1,000 liver cancer patients who received SIR-Spheres—tiny radioactive beads injected into the liver's blood supply to kill tumors. The goal was to see how this treatment is used in real hospitals and how it affects survival, side effects, and quality o…
Sponsor: Cardiovascular and Interventional Radiological Society of Europe • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:34 UTC
-
Quick hepatitis c test during mammograms could catch hidden cases
Knowledge-focused CompletedThis study offered a rapid hepatitis C test to 1,500 women aged 50-74 who were already coming in for breast cancer screening in Montpellier, France. The goal was to see how many women would agree to the extra test and how many had undiagnosed hepatitis C. Women who tested positiv…
Sponsor: University Hospital, Montpellier • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:33 UTC
-
New ultrasound technique aims to better measure liver health
Knowledge-focused CompletedThis study tested a new ultrasound technique called ARFI to measure liver stiffness in 109 people, including healthy volunteers and patients with liver conditions. The goal was to understand normal stiffness values and how they change with disease or treatment. This is an observa…
Phase: NA • Sponsor: University Hospital, Bordeaux • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:33 UTC
-
Your voice may reveal hidden liver risks
Knowledge-focused CompletedThis study looked at whether speech features—like how people sound and what they say—can help detect or predict confusion caused by liver disease (hepatic encephalopathy). Researchers recorded speech tasks from 251 participants with cirrhosis and tracked their thinking skills and…
Sponsor: University of Michigan • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:32 UTC
-
Computer nudge boosts liver referrals
Knowledge-focused CompletedThis study tested whether a pop-up alert in the electronic medical record could help doctors remember to refer patients with fatty liver disease (NASH) to a liver specialist. Thirty doctors from internal medicine, family medicine, and endocrinology took part. The goal was to see …
Phase: NA • Sponsor: University of Kansas Medical Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:32 UTC
-
Liver tissue models could unlock secrets of deadly infections
Knowledge-focused CompletedThis completed study used leftover liver tissue from 36 adults who had surgery to create lab models of early infection. Researchers want to learn how bacteria and viruses first take hold in the liver, which could lead to new ways to prevent or treat serious bloodstream infections…
Sponsor: University of Leicester • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:32 UTC
-
Liver study tests how drug AZD2693 behaves in impaired patients
Knowledge-focused CompletedThis study looked at how a single dose of the drug AZD2693 moves through the body in people with liver impairment compared to healthy volunteers. Researchers measured drug levels in the blood to understand safety and processing differences. A total of 35 adults took part. The goa…
Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:32 UTC
-
Guadeloupe liver infection study reveals key bacterial culprits
Knowledge-focused CompletedThis completed study looked at 58 adults in Guadeloupe with pyogenic liver abscesses, a serious bacterial infection of the liver. Researchers identified the bacteria responsible and tested their antibiotic resistance. The goal was to understand local causes and improve treatment,…
Sponsor: Centre Hospitalier Universitaire de la Guadeloupe • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:31 UTC
-
Standing ultrasound spots hidden liver tumors better than lying down
Knowledge-focused CompletedThis study tested whether having patients stand during an ultrasound helps doctors see small liver tumors near the diaphragm that are often missed when lying down. Researchers scanned 95 people with confirmed liver lesions in three positions: standing, lying on their back, and ly…
Sponsor: The First Hospital of Jilin University • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:31 UTC
-
New surgical clip tool tested in 161 patients
Knowledge-focused CompletedThis study looked at a new device called AE05ML that helps surgeons place clips on blood vessels and other tissues during keyhole surgery. The goal was to see if the device is safe and works well. A total of 161 adults took part in the study.
Sponsor: Teleflex • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:31 UTC
-
Liver Function's impact on drug levels under study
Knowledge-focused CompletedThis study looked at how the body processes a drug called ESK001 in people with different levels of liver function. Researchers gave a single dose to 32 adults, including healthy volunteers and those with mild, moderate, or severe liver impairment. The goal was to measure drug le…
Phase: PHASE1 • Sponsor: Alumis Inc • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:31 UTC
-
Anesthesia may alter gut bugs after liver surgery
Knowledge-focused CompletedThis study looked at how two different anesthesia methods (propofol vs. desflurane) affect gut bacteria and body chemistry in 60 adults undergoing liver tumor removal. Researchers measured changes in gut microbes and blood metabolites to see if anesthesia choice influences recove…
Phase: NA • Sponsor: National Taiwan University Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:30 UTC
-
Researchers measure breathing, strength, and quality of life in hospitalized endocrine patients
Knowledge-focused CompletedThis completed observational study at Uşak University examined 150 adults hospitalized in the endocrinology department. Researchers measured breathing, muscle strength, pain, fatigue, sleep quality, physical activity, balance, and nerve function. The goal was to better understand…
Sponsor: Uşak University • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:30 UTC
-
New diabetes drug tested in patients with liver issues
Knowledge-focused CompletedThis early-stage trial looked at how a single 50mg dose of pyroglutamate rongliflozin capsules behaves in 32 adults with mild or moderate liver damage and type 2 diabetes, compared to healthy volunteers. Researchers measured drug levels in the blood and tracked side effects to un…
Phase: PHASE1 • Sponsor: Sunshine Lake Pharma Co., Ltd. • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:30 UTC
-
Liver transplant risk score under the microscope
Knowledge-focused CompletedThis study looked at 446 liver transplant patients to see if changes in their MELD score (a measure of liver disease severity) could predict who might not survive. Researchers focused on patients with high MELD scores, who are at greater risk. The goal is to better understand how…
Sponsor: University of Jena • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC
-
New study tests how liver problems affect PBC drug processing
Knowledge-focused CompletedThis completed Phase 1 study looked at how the drug seladelpar (Livdelzi) is processed in 24 people with primary biliary cholangitis (PBC) who also have liver impairment. Researchers measured drug levels in the blood and urine to see how the liver condition affects the drug. The …
Phase: PHASE1 • Sponsor: Gilead Sciences • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC
-
Sharper scans may make cancer radiation more precise
Knowledge-focused CompletedThis study tested a new cone-beam CT scanner that takes clearer pictures during radiation therapy for lung, liver, and breast cancers. 31 people participated to see if the new scanner reduces image blurring and improves accuracy. The goal is to help doctors target tumors more pre…
Phase: NA • Sponsor: Varian, a Siemens Healthineers Company • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC
-
Computer model helps cirrhosis patients get blood thinner doses right faster
Knowledge-focused CompletedThis study tested whether a computer program (Simcyp) could help doctors choose the right starting dose of warfarin, a blood thinner, for 21 patients with liver cirrhosis and a blood clot in the portal vein. The goal was to see if the program helped patients reach a safe, effecti…
Phase: PHASE4 • Sponsor: Kafrelsheikh University • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC
-
AI model may personalize liver cancer care after surgery
Knowledge-focused CompletedThis study analyzed data from 1005 liver cancer patients to see who benefits from a treatment called TACE after surgery. Using machine learning, researchers aimed to predict individual patient outcomes. The goal is to help doctors decide whether to recommend TACE or just monitor …
Sponsor: Anhui Provincial Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:28 UTC
-
Can a simple ultrasound spot hidden liver danger in immune disorder patients?
Knowledge-focused CompletedThis study looked at whether ultrasound and stiffness measurements of the liver and spleen can predict a serious condition called portal hypertension in people with common variable immunodeficiency (CVID). Researchers examined 250 CVID patients during routine visits, using non-in…
Sponsor: University Hospital Freiburg • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:28 UTC
-
Cancer surgery recovery: quality of life under the microscope
Knowledge-focused CompletedThis study tracked 295 adults who had high-risk surgery for stomach, esophagus, pancreas, or liver cancer. Researchers measured quality of life before surgery and again at 6 and 12 months after. They also asked patients and their family members if they regretted the decision to h…
Sponsor: University Hospital, Geneva • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:28 UTC
-
Liver study tests how palovarotene behaves in impaired patients
Knowledge-focused CompletedThis completed Phase 1 study looked at how moderate and severe liver impairment changes the way the body handles a single dose of palovarotene, compared to healthy people. Thirty-one participants were split into three groups based on liver function and received up to 10 mg of the…
Phase: PHASE1 • Sponsor: Ipsen • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:26 UTC
-
Wearable device tracks itch and sleep in rare liver disease
Knowledge-focused CompletedThis study tested a wearable sensor called ADAM to measure scratching and sleep patterns in 30 people with primary biliary cholangitis (PBC), a rare liver disease that often causes intense itching and poor sleep. Participants wore the sensor for 7 nights across four 7-day periods…
Sponsor: Ipsen • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:26 UTC
-
Scientists probe Glucagon's role in liver health and diabetes
Knowledge-focused CompletedThis study looked at how the hormone glucagon affects the liver's ability to break down proteins and fats in people with obesity, type 2 diabetes, and fatty liver disease. Researchers wanted to understand if the body becomes resistant to glucagon in these conditions. A total of 2…
Phase: PHASE1, PHASE2 • Sponsor: Adrian Vella • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:25 UTC
-
Small study checks how liver disease affects new drug processing
Knowledge-focused CompletedThis early-stage study tested a single 4 mg dose of the drug elpipodect (MK-8189) in 14 people—some with mild or moderate liver problems and some healthy. Researchers measured how much drug stayed in the blood and for how long. The goal was to see if liver impairment changes drug…
Phase: PHASE1 • Sponsor: Merck Sharp & Dohme LLC • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:24 UTC
-
Gut bacteria may worsen liver disease – new study investigates
Knowledge-focused CompletedThis study looked at how bacteria from the gut might travel to the liver and make liver disease worse in people with hepatitis C. Thirty adults with stable liver disease took part. Researchers used blood tests, MRI scans, and liver tissue samples to measure bacterial movement and…
Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:24 UTC
-
Hepatitis & liver cancer risk explored in immigrant communities
Knowledge-focused CompletedThis study tested 892 African and Asian immigrants for hepatitis B and C to understand how these infections raise the risk of liver cancer. Researchers also checked vaccination rates and tracked new cancer cases over time. No treatment was given; the goal was to gather informatio…
Sponsor: Mayo Clinic • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
Liver Function's impact on experimental brain drug tested
Knowledge-focused CompletedThis study looked at how the experimental drug iclepertin (BI 425809) is processed in people with and without liver problems. 29 adults aged 18-79 took a single dose of the drug. Researchers measured drug levels in the blood and monitored safety to see if liver impairment changes…
Phase: PHASE1 • Sponsor: Boehringer Ingelheim • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
Turkey study reveals hidden fatty liver burden in overweight adults
Knowledge-focused CompletedThis study looked at how common Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) is among 459 adults in Turkey who are at risk due to being overweight, having diabetes, or other metabolic issues. Researchers used a special ultrasound to measure liver fat and stiff…
Sponsor: Maastricht University Medical Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
Ultrasound vs. MRI: which is better for catching liver cancer early?
Knowledge-focused CompletedThis study looked at 211 people with liver cirrhosis to see which screening method works better for detecting liver cancer: an ultrasound every 6 months or an MRI once a year. Participants received both tests, and researchers measured how often each test correctly found cancer. T…
Sponsor: JOON-IL CHOI • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
Liver MRI could spot dangerous drug interactions early
Knowledge-focused CompletedThis study tested whether a special MRI scan can measure how two common drugs, metformin and ciclosporin, affect the liver. Twelve healthy volunteers received the MRI dye gadoxetate before and after taking the drugs. The goal was to see if the scan could detect changes in liver f…
Sponsor: Sheffield Teaching Hospitals NHS Foundation Trust • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
Liver scan may predict deadly failure after big operations
Knowledge-focused CompletedThis study tested whether a special liver scan (hepatobiliary scintigraphy) can predict liver failure in 326 patients undergoing major liver surgery. The scan measures how well the remaining liver works, which may be more useful than just measuring its size. If accurate, it could…
Phase: NA • Sponsor: University Hospital, Lille • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
Can a blood protein predict better diabetes treatment?
Knowledge-focused CompletedThis completed study in 130 adults with type 2 diabetes and fatty liver disease tested whether a blood marker called adiponectin can predict how well certain diabetes drugs reduce liver fat. Participants received either an SGLT2 inhibitor, a GLP-1 receptor agonist, or both for si…
Phase: NA • Sponsor: Moscow Regional Research and Clinical Institute (MONIKI) • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
New test and tiny particles could help manage bleeding in liver disease
Knowledge-focused CompletedThis study looked at how blood clots in people with liver cirrhosis, a condition that can cause bleeding problems. Researchers used a special machine called T-TAS to measure clotting in blood samples from 60 patients. They also tested whether tiny particles that act like platelet…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
Stress and depression may worsen liver disease in korean americans with hepatitis b
Knowledge-focused CompletedThis study looked at how factors like chronic stress and depression might speed up liver damage in Korean Americans with chronic hepatitis B. Researchers followed 365 participants over time, collecting health records, hair samples, and interview data. The goal was to understand w…
Sponsor: Thomas Jefferson University • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
Liver disease Patients' vaccine response under the microscope
Knowledge-focused CompletedThis study looked at how people with chronic liver disease (like hepatitis B, C, or fatty liver) respond to COVID-19 vaccines. About 233 adults had three visits over a year to check their immune response and see if they got COVID-19. The goal was to understand if liver disease af…
Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:09 UTC
-
Bile duct issues may shorten cancer treatment, study finds
Knowledge-focused CompletedThis study looked at medical records of 729 people in Japan with biliary tract cancer that could not be removed by surgery. Researchers wanted to see if bile duct problems during first treatment affected how long patients could stay on that treatment. The study did not test any n…
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:09 UTC
-
Blood tests may reveal hidden liver damage in anorexia patients
Knowledge-focused CompletedThis study aimed to find new blood markers that can show liver damage in people with anorexia nervosa. Researchers compared blood samples from 19 patients with and without signs of liver injury. The goal is to improve detection and understanding of liver problems in this conditio…
Sponsor: Nantes University Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:09 UTC
-
New scope method challenges standard liver biopsy
Knowledge-focused CompletedThis study compared two procedures for getting a liver biopsy and measuring liver pressure in people with chronic liver disease or cirrhosis. One method uses a scope through the mouth (endoscopic ultrasound), the other goes through a vein in the neck (transjugular). The goal was …
Phase: NA • Sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:09 UTC
-
10,000 seniors studied to predict fatty liver dangers
Knowledge-focused CompletedThis study looked at 10,000 older adults (age 60+) with fatty liver disease to find out what increases their risk for serious liver problems like scarring, cirrhosis, or liver cancer. Researchers used medical records and yearly check-ups to build a computer model that predicts th…
Sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:09 UTC
-
Hidden liver scarring found in anorexia patients
Knowledge-focused CompletedThis study looked at how common liver scarring (fibrosis) is in people with anorexia nervosa. Researchers used a special scan called Fibroscan to measure liver stiffness in 43 patients when they were admitted to the hospital. The goal was to learn more about liver health in this …
Sponsor: Nantes University Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:09 UTC
-
Hidden brain fog in liver disease: new study sheds light
Knowledge-focused CompletedThis study looked at 82 adults with cirrhosis and portal hypertension (high blood pressure in the liver) to find out how many have minimal hepatic encephalopathy (MHE) — a mild form of brain fog that can affect thinking. Researchers used simple blood tests and thinking exercises …
Phase: NA • Sponsor: IHU Strasbourg • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:08 UTC
-
New study reveals hidden kidney risks in liver cirrhosis patients
Knowledge-focused CompletedThis study looked at how often acute kidney injury happens in people with liver cirrhosis, and what factors might increase the risk. Researchers at Sohag University Hospital followed 180 adult patients with cirrhosis, excluding those with pre-existing kidney disease or other majo…
Sponsor: Sohag University • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:07 UTC
-
New biomarker may predict which cancer drugs work best
Knowledge-focused CompletedThis completed study tested whether a new biomarker called 'mass response' can predict how well a cancer therapy will work. Researchers collected tumor cells from 72 patients with various cancers through fluid drainage or biopsies. The goal was to see if this biomarker could guid…
Sponsor: Travera Inc • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:06 UTC
-
Dundee study tests if HCV treatment stops spread among drug users
Knowledge-focused CompletedThis study looked at whether treating hepatitis C in people who inject drugs can prevent the virus from spreading to others. Researchers analyzed health records of about 2,800 people in NHS Tayside who were tested or treated for hepatitis C. No new treatments or procedures were g…
Sponsor: University of Dundee • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:06 UTC
-
Liver scanner accuracy put to the test in new study
Knowledge-focused CompletedThis study looked at how consistent FibroScan, a non-invasive device that measures liver stiffness and fat, is when used by different operators on different days. 108 adults with fatty liver or alcohol-related liver disease had multiple scans and blood tests over two visits. The …
Phase: NA • Sponsor: Echosens • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:06 UTC
-
Can a phone app help fight fatty liver disease?
Knowledge-focused CompletedThis study tested whether a mobile health app called EL-FIT could help people with nonalcoholic steatohepatitis (NASH) exercise safely at home. Seventeen adults with NASH used the app and a Fitbit to do daily exercise as they wished. The main goal was to see if it was feasible an…
Phase: NA • Sponsor: Milton S. Hershey Medical Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:05 UTC
-
Could T-DXd outperform standard care for multiple HER2-Positive cancers? new study investigates
Knowledge-focused CompletedThis study looks at whether the drug T-DXd works better than standard treatments for people with several types of HER2-positive solid tumors. Researchers will compare data from previous T-DXd trials with real-world medical records of patients who received standard care. The goal …
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:05 UTC
-
New genomic risk model aims to make personalized prevention accessible to all
Knowledge-focused CompletedThis study tested a program called GRACE that helps primary care patients assess their risk for diseases like heart disease, cancer, and liver disease using family health history. Researchers enrolled 245 patients from five clinics, including low-resource settings, to see how man…
Phase: NA • Sponsor: Duke University • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:05 UTC
-
New 3D method may improve tumor measurement accuracy
Knowledge-focused CompletedThis study looked at 120 adults with breast, pancreatic, or biliary cancer to see if a new 3D measurement method (TDTP-RECIST) is better than the standard way (RECIST 1.1) for tracking tumor shrinkage before surgery. Researchers compared imaging results with actual tumor tissue r…
Sponsor: Shanghai Zhongshan Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:04 UTC
-
Liver biopsy showdown: EUS or needle – patients decide!
Knowledge-focused CompletedThis study compared how patients feel about two ways to take a small sample of liver tissue: one using a needle through the skin (percutaneous) and another using a thin tube through the mouth (EUS-guided). 102 adults with chronic liver disease were randomly assigned to one method…
Sponsor: University Hospital Muenster • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:04 UTC
-
Grip strength may reveal hidden clues about liver vein pressure
Knowledge-focused CompletedThis study looked at 64 adults with liver cirrhosis and a history of variceal bleeding who were scheduled for a TIPS procedure. Researchers measured handgrip strength and then checked how it changed blood pressure in the portal and left gastric veins. The goal was to see if muscl…
Sponsor: Shanxi Provincial People's Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:04 UTC
-
Leg strength test may help spot frailty in liver patients
Knowledge-focused CompletedThis study of 60 people with cirrhosis measured quadriceps (thigh) strength and compared it to standard frailty and malnutrition scores. The goal was to see if a simple leg strength test could replace more complex frailty assessments. No treatment was given; it was purely an obse…
Phase: NA • Sponsor: University Hospital, Clermont-Ferrand • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:04 UTC
-
Gut microbes linked to fatty liver – new study explores connection
Knowledge-focused CompletedThis study looked at 38 adults with non-alcoholic fatty liver disease to see if gut bacteria are getting too close to the gut lining, which might worsen liver health. Researchers used a sigmoidoscopy to take tissue samples and measured the distance of microbes from intestinal cel…
Sponsor: AdventHealth Translational Research Institute • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:04 UTC
-
450 transgender people join landmark health study in southeast asia
Knowledge-focused CompletedThis study followed 450 transgender people (300 HIV-negative and 150 living with HIV) from community health centers in Thailand, Vietnam, and the Philippines for 24 months. Researchers tracked new HIV infections, mental health, and social factors like stigma and violence using su…
Sponsor: Institute of HIV Research and Innovation Foundation, Thailand • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:02 UTC
-
Scientists dig into Obesity's secrets with tissue samples
Knowledge-focused CompletedThis study collected blood, stomach, liver, intestine, and fat tissue from 360 severely obese patients undergoing bariatric surgery. The goal was to better understand how obesity and surgery affect the body, especially the digestive system. Researchers hope this knowledge will le…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:02 UTC
-
Heart safety check for experimental liver drug
Knowledge-focused CompletedThis early-stage trial tested whether a single dose of hydronidone, an experimental drug for liver fibrosis, changes the heart's electrical activity (QTc interval) in 48 healthy Chinese adults. Participants received one of three doses or a placebo, and researchers measured how th…
Phase: PHASE1 • Sponsor: Beijing Continent Pharmaceutical Co, Ltd. • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:02 UTC
-
Fatty liver clues found in immune proteins?
Knowledge-focused CompletedThis completed study examined immune semaphorin proteins in the liver and fat tissue of 148 obese patients with non-alcoholic fatty liver disease (NAFLD). Researchers aimed to understand how these proteins relate to inflammation and liver damage. The study did not test any treatm…
Phase: NA • Sponsor: Centre Hospitalier Universitaire de Nice • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:02 UTC
-
Time-Restricted eating may slow aging in overweight adults
Knowledge-focused CompletedThis completed study looked at whether eating only during a specific daily window (time-restricted eating) can slow the aging process in 176 adults who are overweight or have early fatty liver disease. Participants followed a Mediterranean diet with or without calorie restriction…
Phase: NA • Sponsor: IMDEA Food • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:00 UTC
-
Scientists peer into liver cancer cells to unlock secrets
Knowledge-focused CompletedThis study looked at liver cancer cells from 30 patients to understand how they differ from healthy cells. Researchers isolated these cells to create 3D lab models called organoids. The goal was to learn more about the behavior and genetics of liver cancer, not to test a new trea…
Phase: NA • Sponsor: Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:00 UTC
-
Liver transplant study may unlock clues to artery hardening
Knowledge-focused CompletedThis pilot study looked at 38 liver transplant patients to see if liver failure lowers blood levels of pyrophosphate, a natural substance that prevents calcium buildup in tissues. Researchers measured pyrophosphate before and after transplant and checked liver tissue for a relate…
Phase: NA • Sponsor: Centre Hospitalier Universitaire de Nice • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:00 UTC
-
Fatty liver may be a hidden clue for heart trouble
Knowledge-focused CompletedThis study looked at whether fatty liver disease can be an early warning sign for heart disease, separate from known risk factors. Researchers measured blood markers of blood vessel damage in 63 people aged 50-69 who were already at high risk for heart problems. The goal was to b…
Sponsor: IMDEA Food • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:00 UTC
-
New liver transplant rules may drive up costs, study finds
Knowledge-focused CompletedThis study looked at how a new U.S. policy for distributing donated livers (started in 2020) affected costs for liver transplants at one hospital in Dallas. Researchers compared costs and transplant volumes for 186 patients before and after the policy change. The goal was to unde…
Sponsor: Methodist Health System • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:00 UTC
-
Researchers uncover key risk factors for severe NASH fibrosis
Knowledge-focused CompletedThis study examined medical records of 263 adults with NASH to see how factors like age, other health problems, and medications relate to the severity of liver scarring. The goal was to identify which patients are at higher risk for advanced fibrosis. The findings may help doctor…
Sponsor: Methodist Health System • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:00 UTC
-
Small study hopes to personalize anesthesia for liver transplant patients
Knowledge-focused CompletedThis completed study looked at 3 liver transplant patients to see if muscle loss (sarcopenia) changes how the body responds to the muscle relaxant rocuronium. Researchers measured hand grip strength and used a questionnaire to diagnose sarcopenia before surgery, then tracked how …
Phase: NA • Sponsor: Inonu University • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:00 UTC
-
Digital biopsy score may predict liver failure risk in fatty liver patients
Knowledge-focused CompletedThis study looked at whether a computer analysis of liver biopsy images (called FibroNest Ph-FCS) can predict future liver complications in people with a type of fatty liver disease called MASLD. Researchers reviewed medical records from 1,578 patients to see if the digital score…
Sponsor: PharmaNest, Inc • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:00 UTC
-
Liver function may affect how itch drug works in body
Knowledge-focused CompletedThis early-phase study looked at how the body breaks down nalbuphine extended-release tablets in people with mild, moderate, or severe liver impairment compared to healthy volunteers. It also explored whether the drug could relieve itching in those with liver problems. The study …
Phase: PHASE1 • Sponsor: Trevi Therapeutics • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:03 UTC
-
AI reads MRI scans to predict liver cancer survival
Knowledge-focused CompletedThis completed study looked at 169 patients with a type of liver cancer called intrahepatic cholangiocarcinoma. Researchers used MRI scans and machine learning to measure scar tissue and a protein linked to tumor growth. The goal was to see if these features could predict how lon…
Sponsor: First Affiliated Hospital, Sun Yat-Sen University • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:03 UTC
-
New drug tested in people with liver disease
Knowledge-focused CompletedThis study looked at how the body handles a single shot of fazirsiran in 34 people with mild, moderate, or severe liver problems, compared to those with healthy livers. Participants were followed for 6 months after the injection. The goal was to measure drug levels and check for …
Phase: PHASE1 • Sponsor: Takeda • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:03 UTC
-
New model helps surgeons choose best operation for rare liver cancer
Knowledge-focused CompletedThis study tested a computer model that helps surgeons decide the best type of surgery for patients with a rare form of liver cancer that has spread into the bile ducts. The model uses patient scans and medical history to recommend whether to remove part of the bile duct or just …
Sponsor: First Affiliated Hospital, Sun Yat-Sen University • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:02 UTC
-
Can a virtual community curb Opioid-Linked HIV and hepatitis c in rural america?
Knowledge-focused CompletedThis study tested a digital, community-led program to help people in rural Appalachia and the Midwest reduce their risk of HIV and hepatitis C, often linked to opioid use. Over 500 adults took part, with half currently or previously using illicit substances. The program included …
Phase: NA • Sponsor: University of Pennsylvania • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:02 UTC
-
Cord clamping delay may boost jaundice risk in At-Risk newborns
Knowledge-focused CompletedThis study looked at whether waiting 60 seconds to clamp the umbilical cord (delayed cord clamping) raises bilirubin levels in newborns whose mothers had a previous child with jaundice needing treatment. Twenty mothers and their babies took part. The goal was to see if delayed cl…
Phase: NA • Sponsor: The University of Texas Health Science Center, Houston • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:02 UTC
-
New math models could save lives on liver transplant waitlist
Knowledge-focused CompletedThis study aimed to create new mathematical models to better predict which patients with severe liver disease are at highest risk of dying while waiting for a liver transplant. Researchers analyzed data from 501 adults on the French national transplant waiting list. The goal is t…
Phase: NA • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:01 UTC
-
MASH awareness survey completed: no treatment, just insights
Knowledge-focused CompletedThis study used online questionnaires to understand how well healthcare providers and people with or at risk for MASH (a liver disease) understand the links between MASH and heart, kidney, and metabolic conditions. About 1,330 participants completed the 25-minute survey. The goal…
Sponsor: Novo Nordisk A/S • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:01 UTC
-
Real-world study reveals how well new liver cancer combo works in patients with cirrhosis
Knowledge-focused CompletedThis study looked at how safe and effective a combination of two drugs (Atezolizumab and Bevacizumab) is for people with liver cancer and cirrhosis, compared to standard pills (tyrosine kinase inhibitors). Researchers followed 38 patients to see how long they lived and how their …
Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:01 UTC
-
New drug tested in patients with liver disease
Knowledge-focused CompletedThis study looked at how the body processes a single dose of the drug AMG 133 in people with different levels of liver impairment compared to those with healthy livers. Thirty-six adults took part, and researchers measured drug levels in the blood and checked for side effects. Th…
Phase: PHASE1 • Sponsor: Amgen • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:00 UTC
-
Computer-Guided statin dosing shows promise for liver patients
Knowledge-focused CompletedThis study tested whether a computer program could help doctors choose the right dose of simvastatin for people with cirrhosis and high blood pressure in the liver. Twenty-two patients received either 5 mg or 15 mg of simvastatin daily for three months. Researchers measured chang…
Phase: PHASE4 • Sponsor: Kafrelsheikh University • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:00 UTC
-
New blood test spots silent spread of bile duct cancer before surgery
Knowledge-focused CompletedThis study tested whether a blood test that looks at tiny particles called exosomes can find cancer that has spread but is not visible on scans in people with a type of bile duct cancer (intrahepatic cholangiocarcinoma). The goal was to help doctors know who needs stronger treatm…
Sponsor: City of Hope Medical Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:00 UTC
-
New Free-Breathing MRI could make liver scans easier for kids
Knowledge-focused CompletedThis study tested new MRI and MRE techniques that let children breathe normally during scans, instead of holding their breath. The goal was to measure liver fat and stiffness more comfortably and accurately in kids with fatty liver disease. 135 children aged 6-17 took part, and t…
Sponsor: University of California, Los Angeles • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:00 UTC
-
Liver function and drug safety: new study on varegacestat
Knowledge-focused CompletedThis study looked at how the drug varegacestat moves through the body in people with liver problems compared to healthy people. About 35 adults took a single dose, and researchers measured drug levels and side effects. The goal was to understand if liver impairment changes how th…
Phase: PHASE1 • Sponsor: Immunome, Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:00 UTC
-
Fatty liver may signal hidden heart danger
Knowledge-focused CompletedThis completed study examined 292 people with non-alcoholic fatty liver disease (NAFLD) to see if liver scarring is linked to heart disease risk. Researchers used non-invasive tests like the coronary calcium score and liver elastography. The goal was to better understand how to s…
Sponsor: Clinique Pasteur • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:10 UTC
-
Lifting weights for just 4 weeks may boost breathing muscle and cut liver fat in seniors
Knowledge-focused CompletedThis study looked at whether a 4-week moderate resistance training program could improve diaphragm thickness, liver fat, and quality of life in healthy men aged 60-75. Thirty participants were split into an exercise group or a control group that kept their normal routine. Researc…
Phase: NA • Sponsor: Gümüşhane Universıty • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:10 UTC
-
CT scan clues may guide better liver cancer care
Knowledge-focused CompletedThis study looked at 324 adults with intermediate-stage liver cancer to see if CT scan features could predict how well they would respond to a combination treatment of targeted therapy and a procedure that blocks the tumor's blood supply. The goal was to find out if certain scan …
Sponsor: First Affiliated Hospital, Sun Yat-Sen University • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:10 UTC
-
Carotid ultrasound may help guide fluid management in liver transplants
Knowledge-focused CompletedThis completed study tested whether a simple ultrasound of the carotid artery during liver transplant surgery can help doctors assess a patient's fluid status. Researchers measured changes in blood flow velocity in the carotid artery in 42 adult liver transplant patients. The goa…
Sponsor: Inonu University • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:10 UTC
-
Study uncovers hurdles to hepatitis b care for immigrants in the US
Knowledge-focused CompletedThis completed study looked at 274 foreign-born adults in the US with chronic hepatitis B to understand why many do not get proper follow-up care. Participants completed a one-time survey about their background, immigration experience, and healthcare access. The goal is to identi…
Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:09 UTC
-
Liver impairment drug study completed: what happens to BPN14770?
Knowledge-focused CompletedThis study looked at how the drug BPN14770 is handled by the body in people with mild, moderate, or severe liver impairment compared to healthy people. A total of 32 adults took a single dose of the drug. Researchers measured drug levels in the blood and checked for side effects.…
Phase: PHASE1 • Sponsor: Shionogi • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:09 UTC
-
How does a new drug behave in a damaged liver?
Knowledge-focused CompletedThis completed Phase 1 study looked at how the drug MK-8527 moves through the body in people with mild or moderate liver impairment compared to healthy volunteers. Researchers measured drug levels in the blood over time to understand how liver function affects the drug. The study…
Phase: PHASE1 • Sponsor: Merck Sharp & Dohme LLC • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:08 UTC
-
Fatty liver study tracks 922 patients to uncover hidden risks
Knowledge-focused CompletedThis study followed 922 adults with metabolic fatty liver disease (MASLD) for up to 2 years. Researchers tracked changes in liver health and looked for clinical and metabolic factors that predict worsening disease, including liver scarring, serious liver events, heart problems, a…
Sponsor: First Affiliated Hospital of Chongqing Medical University • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:08 UTC
-
New score may help doctors predict ICU outcomes for liver patients
Knowledge-focused CompletedThis study tested a new scoring system called the Intensive Care Cirrhosis Outcome (ICCO) score to see how well it predicts survival in cirrhosis patients admitted to the ICU. Researchers calculated the score for 150 adult patients using routine lab tests and tracked their outcom…
Sponsor: Assiut University • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:08 UTC
-
Tiny study tests how liver disease changes drug processing
Knowledge-focused CompletedThis completed Phase 1 study looked at how the drug bomedemstat behaves in people with mild or moderate liver impairment compared to healthy volunteers. Nine participants received a single dose, and researchers measured drug levels in the blood. The goal is to understand if liver…
Phase: PHASE1 • Sponsor: Merck Sharp & Dohme LLC • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:07 UTC
-
Liver function may change how prostate cancer drug works
Knowledge-focused CompletedThis study looked at how the experimental prostate cancer drug opevesostat moves through the body in men with moderate liver impairment compared to healthy men. Sixteen male participants received a single dose, and researchers measured drug levels over time. The goal was to under…
Phase: PHASE1 • Sponsor: Merck Sharp & Dohme LLC • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:07 UTC
-
Simple frailty quiz may help predict chemo risks for seniors with stomach or bowel cancer
Knowledge-focused CompletedThis study looked at whether two simple frailty questionnaires (G8 and VES-13) can predict serious side effects from chemotherapy in people 65 and older with gastrointestinal cancers. Researchers followed 72 patients receiving standard chemotherapy and checked their frailty, nutr…
Sponsor: Ankara Etlik City Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:07 UTC
-
New drug for fatty liver disease first tested in healthy volunteers
Knowledge-focused CompletedThis early-stage study tested the safety of a new drug called ACT500 in 72 healthy Chinese adults. Participants received either the drug or a placebo, and researchers monitored side effects and how the drug moved through the body. The goal was not to treat disease but to gather e…
Phase: PHASE1 • Sponsor: Xiamen Amoytop Biotech Co., Ltd. • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:06 UTC
-
Researchers watch how SBRT works for liver and pancreatic tumors
Knowledge-focused CompletedThis study looked at how safe and effective a precise type of radiation therapy (SBRT) is for treating liver tumors, liver metastases, and pancreatic tumors. It involved 65 adult patients who were already scheduled for SBRT. The goal was to monitor and improve the treatment proce…
Phase: NA • Sponsor: Institute of Oncology Ljubljana • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:06 UTC
-
Long-Term PBC study reveals Real-World treatment patterns
Knowledge-focused CompletedThis study followed 711 adults with primary biliary cholangitis (PBC) for 5 years to see how the disease is managed in everyday medical practice. Researchers collected data on treatments, lab results, and side effects, and also stored blood samples for future genetic research. Th…
Sponsor: Target PharmaSolutions, Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:05 UTC
-
Liver cancer patients: do pre-transplant drugs improve outcomes?
Knowledge-focused CompletedThis study looked back at data from 484 liver cancer patients who had a liver transplant to see if taking certain cancer drugs (tyrosine kinase inhibitors) before the transplant helped them live longer or kept the cancer from coming back. The researchers checked survival rates, c…
Sponsor: Hu Liangshuo • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:05 UTC
-
Video education boosts drug compliance in liver transplant patients, study finds
Knowledge-focused CompletedThis study tested whether video-based education helps liver transplant patients adapt to their disease and use medications correctly. 90 adult patients were split into three groups: two received different video trainings, and one got standard care. Researchers measured adaptation…
Phase: NA • Sponsor: Inonu University • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:05 UTC
-
Liver transplant access: are alcoholic patients treated fairly?
Knowledge-focused CompletedThis completed study looked at 574 hospitalized adults with end-stage liver disease to see if alcoholic patients had the same chance of getting on the national liver transplant waiting list as non-alcoholic patients. The goal was to find out if non-medical reasons limit access fo…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:05 UTC
-
New NAFLD drug safety checked in patients with liver damage
Knowledge-focused CompletedThis study tested a single injection of a new drug (NNC0194-0499) for non-alcoholic fatty liver disease in 33 people with various degrees of liver impairment and healthy volunteers. The goal was to see how the liver processes the drug and whether it is safe. Results will help det…
Phase: PHASE1 • Sponsor: Novo Nordisk A/S • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:05 UTC
-
Light sensor may spot kidney trouble during liver transplants
Knowledge-focused CompletedThis study tested whether a non-invasive light sensor (near-infrared spectroscopy) placed on the skin over the kidney could measure oxygen levels during liver transplant surgery. Researchers monitored 41 patients to see if this method gives useful information about kidney functio…
Sponsor: Inonu University • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:04 UTC
-
Liver transplant survival: does Donor-Recipient gender matter?
Knowledge-focused CompletedThis study looked at over 1,100 liver transplant patients to see if having a donor of a different gender affects long-term survival. Researchers followed patients for up to 10 years after transplant. The goal is to understand whether gender mismatch is a risk factor, which could …
Sponsor: University of Jena • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:04 UTC
-
Liver study aims to make cancer drug safer for patients with liver disease
Knowledge-focused CompletedThis study looks at how moderate liver problems change the way the body handles sevabertinib, an experimental cancer drug for tumors with HER2 mutations. About 20 people—10 with liver impairment and 10 healthy volunteers—will take a single dose and have their blood levels measure…
Phase: PHASE1 • Sponsor: Bayer • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:03 UTC